CN114437038A - Pyridazine alkyne compound and application thereof - Google Patents
Pyridazine alkyne compound and application thereof Download PDFInfo
- Publication number
- CN114437038A CN114437038A CN202111305068.7A CN202111305068A CN114437038A CN 114437038 A CN114437038 A CN 114437038A CN 202111305068 A CN202111305068 A CN 202111305068A CN 114437038 A CN114437038 A CN 114437038A
- Authority
- CN
- China
- Prior art keywords
- substituted
- alkyl
- unsubstituted
- membered
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Pyridazine alkyne compound Chemical class 0.000 title claims description 81
- 150000001875 compounds Chemical class 0.000 claims abstract description 113
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 239000000651 prodrug Substances 0.000 claims abstract description 29
- 229940002612 prodrug Drugs 0.000 claims abstract description 29
- 239000012453 solvate Substances 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 16
- 125000001424 substituent group Chemical group 0.000 claims description 49
- 229910052757 nitrogen Inorganic materials 0.000 claims description 43
- 125000005842 heteroatom Chemical group 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 32
- 150000002367 halogens Chemical class 0.000 claims description 32
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 229910052717 sulfur Inorganic materials 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 238000006467 substitution reaction Methods 0.000 claims description 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 13
- 229910052801 chlorine Inorganic materials 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 229930192474 thiophene Natural products 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims description 3
- 125000005049 dihydrooxadiazolyl group Chemical group O1N(NC=C1)* 0.000 claims description 3
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 claims description 3
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 claims description 2
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 claims description 2
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 2
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 claims description 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims description 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 claims description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 2
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims description 2
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims 3
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 abstract description 29
- 102100022464 5'-nucleotidase Human genes 0.000 abstract description 24
- 238000002360 preparation method Methods 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 123
- 238000006243 chemical reaction Methods 0.000 description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 46
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- 230000015572 biosynthetic process Effects 0.000 description 45
- 238000003786 synthesis reaction Methods 0.000 description 45
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 42
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 33
- 239000012074 organic phase Substances 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
- 239000003921 oil Substances 0.000 description 30
- 238000005160 1H NMR spectroscopy Methods 0.000 description 29
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- 239000000203 mixture Substances 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
- 239000012043 crude product Substances 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 239000003208 petroleum Substances 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- 238000000926 separation method Methods 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 235000011152 sodium sulphate Nutrition 0.000 description 15
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 238000010828 elution Methods 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- NQUQLGGUKAKWMS-SVRRBLITSA-N 3-chloro-4-[(1S,2S)-2-(difluoromethyl)cyclopropyl]-6-(2,4-dimethoxypyrimidin-5-yl)pyridazine Chemical compound ClC=1N=NC(=CC=1[C@@H]1[C@H](C1)C(F)F)C=1C(=NC(=NC=1)OC)OC NQUQLGGUKAKWMS-SVRRBLITSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000004007 reversed phase HPLC Methods 0.000 description 9
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 8
- MMXAFRNMNJZPHW-APPZFPTMSA-N CC#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(N2)=O)=CNC2=O)N=N1 Chemical compound CC#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(N2)=O)=CNC2=O)N=N1 MMXAFRNMNJZPHW-APPZFPTMSA-N 0.000 description 8
- OCVATHBJWBLVEK-SCZZXKLOSA-N CCC#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(N2)=O)=CNC2=O)N=N1 Chemical compound CCC#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(N2)=O)=CNC2=O)N=N1 OCVATHBJWBLVEK-SCZZXKLOSA-N 0.000 description 8
- POTGPTQTXHDVQV-PWSUYJOCSA-N CN1N=CC(C#CC2=C([C@@H](C3)[C@H]3C(F)F)C=C(C(C(N3)=O)=CNC3=O)N=N2)=C1 Chemical compound CN1N=CC(C#CC2=C([C@@H](C3)[C@H]3C(F)F)C=C(C(C(N3)=O)=CNC3=O)N=N2)=C1 POTGPTQTXHDVQV-PWSUYJOCSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- NHJQVRDVHGCJKY-PWSUYJOCSA-N O=C(C(C1=CC([C@@H](C2)[C@H]2C(F)F)=C(C#CC2CCC2)N=N1)=CN1)NC1=O Chemical compound O=C(C(C1=CC([C@@H](C2)[C@H]2C(F)F)=C(C#CC2CCC2)N=N1)=CN1)NC1=O NHJQVRDVHGCJKY-PWSUYJOCSA-N 0.000 description 8
- NKHYNHXZHYGMEC-MNOVXSKESA-N O=C(C(C1=CC([C@@H]2[C@@H](CF)C2)=C(C#CC2CC2)N=N1)=CN1)NC1=O Chemical compound O=C(C(C1=CC([C@@H]2[C@@H](CF)C2)=C(C#CC2CC2)N=N1)=CN1)NC1=O NKHYNHXZHYGMEC-MNOVXSKESA-N 0.000 description 8
- YCWIFLUXOMWSIW-GXSJLCMTSA-N O=C(C(C1=CC([C@H](C2)[C@@H]2C(F)F)=C(C#CC2CC2)N=N1)=CN1)NC1=O Chemical compound O=C(C(C1=CC([C@H](C2)[C@@H]2C(F)F)=C(C#CC2CC2)N=N1)=CN1)NC1=O YCWIFLUXOMWSIW-GXSJLCMTSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 229960005305 adenosine Drugs 0.000 description 8
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 8
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 8
- AMWPVDIRLLKSNX-SCZZXKLOSA-N CC(C)(C#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(N2)=O)=CNC2=O)N=N1)O Chemical compound CC(C)(C#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(N2)=O)=CNC2=O)N=N1)O AMWPVDIRLLKSNX-SCZZXKLOSA-N 0.000 description 7
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 7
- YCWIFLUXOMWSIW-KOLCDFICSA-N O=C(C(C1=CC([C@@H](C2)[C@H]2C(F)F)=C(C#CC2CC2)N=N1)=CN1)NC1=O Chemical compound O=C(C(C1=CC([C@@H](C2)[C@H]2C(F)F)=C(C#CC2CC2)N=N1)=CN1)NC1=O YCWIFLUXOMWSIW-KOLCDFICSA-N 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 229940125782 compound 2 Drugs 0.000 description 7
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- AQPYFAYLGMEWCD-HRFVKAFMSA-N (1S,2S)-2-(difluoromethyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@@H]1C(F)F AQPYFAYLGMEWCD-HRFVKAFMSA-N 0.000 description 6
- UGMUWEAHMRSJRQ-DMTCNVIQSA-N (1S,2S)-2-(fluoromethyl)cyclopropane-1-carboxylic acid Chemical compound OC([C@@H]1[C@@H](CF)C1)=O UGMUWEAHMRSJRQ-DMTCNVIQSA-N 0.000 description 6
- NQNJPDBEVSZYTO-MNOVXSKESA-N CC(C)[C@@H](C1)[C@H]1C1=C(C#CC)N=NC(C(C(N2)=O)=CNC2=O)=C1 Chemical compound CC(C)[C@@H](C1)[C@H]1C1=C(C#CC)N=NC(C(C(N2)=O)=CNC2=O)=C1 NQNJPDBEVSZYTO-MNOVXSKESA-N 0.000 description 6
- JISBTLVTLVMQKC-YPMHNXCESA-N COC1=NC(OC)=NC=C1C1=CC([C@@H](C2)[C@H]2C(F)F)=C(C#CC2CC2)N=N1 Chemical compound COC1=NC(OC)=NC=C1C1=CC([C@@H](C2)[C@H]2C(F)F)=C(C#CC2CC2)N=N1 JISBTLVTLVMQKC-YPMHNXCESA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 6
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 6
- LUUSYESYLFJQHB-WHFBIAKZSA-N ethyl (1S,2S)-2-(difluoromethyl)cyclopropane-1-carboxylate Chemical compound CCOC(=O)[C@H]1C[C@@H]1C(F)F LUUSYESYLFJQHB-WHFBIAKZSA-N 0.000 description 6
- WPTIXUDEALSQOF-OLZOCXBDSA-N ethyl (1s,2s)-2-(phenylmethoxymethyl)cyclopropane-1-carboxylate Chemical compound CCOC(=O)[C@H]1C[C@@H]1COCC1=CC=CC=C1 WPTIXUDEALSQOF-OLZOCXBDSA-N 0.000 description 6
- MDWXTLNIZCHBJE-RITPCOANSA-N ethyl (1s,2s)-2-formylcyclopropane-1-carboxylate Chemical compound CCOC(=O)[C@H]1C[C@@H]1C=O MDWXTLNIZCHBJE-RITPCOANSA-N 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- GSNLYQDUCHEFFQ-HRFVKAFMSA-N (1s,2s)-2-(trifluoromethyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@@H]1C(F)(F)F GSNLYQDUCHEFFQ-HRFVKAFMSA-N 0.000 description 5
- BRVQFDJETHFEQY-WHFBIAKZSA-N (1s,2s)-2-ethoxycarbonylcyclopropane-1-carboxylic acid Chemical compound CCOC(=O)[C@H]1C[C@@H]1C(O)=O BRVQFDJETHFEQY-WHFBIAKZSA-N 0.000 description 5
- REYZXWIIUPKFTI-YFKPBYRVSA-N (2r)-2-propan-2-yloxirane Chemical compound CC(C)[C@@H]1CO1 REYZXWIIUPKFTI-YFKPBYRVSA-N 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- TZVFQTLGABAODV-KOLCDFICSA-N CC#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(OC)=N2)=CN=C2OC)N=N1 Chemical compound CC#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(OC)=N2)=CN=C2OC)N=N1 TZVFQTLGABAODV-KOLCDFICSA-N 0.000 description 5
- KBINTOCNLWDMSO-KOLCDFICSA-N CC(C)C#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(N2)=O)=CNC2=O)N=N1 Chemical compound CC(C)C#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(N2)=O)=CNC2=O)N=N1 KBINTOCNLWDMSO-KOLCDFICSA-N 0.000 description 5
- AZFVTLJQILCTSP-YPMHNXCESA-N CC(C)C#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(OC)=N2)=CN=C2OC)N=N1 Chemical compound CC(C)C#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(OC)=N2)=CN=C2OC)N=N1 AZFVTLJQILCTSP-YPMHNXCESA-N 0.000 description 5
- DWVOXJBWQJKIQQ-ZJUUUORDSA-N CC(C)[C@@H](C1)[C@H]1C(C=C(C(C(OC)=N1)=CN=C1OC)N=N1)=C1Cl Chemical compound CC(C)[C@@H](C1)[C@H]1C(C=C(C(C(OC)=N1)=CN=C1OC)N=N1)=C1Cl DWVOXJBWQJKIQQ-ZJUUUORDSA-N 0.000 description 5
- HQAKTCUEKKXZGZ-RQJHMYQMSA-N CC(C)[C@@H](C1)[C@H]1C(C=C(N=N1)Cl)=C1Cl Chemical compound CC(C)[C@@H](C1)[C@H]1C(C=C(N=N1)Cl)=C1Cl HQAKTCUEKKXZGZ-RQJHMYQMSA-N 0.000 description 5
- ZHHGMIGQLRIYSG-OLZOCXBDSA-N CC(C)[C@@H](C1)[C@H]1C1=C(C#CC)N=NC(C(C(OC)=N2)=CN=C2OC)=C1 Chemical compound CC(C)[C@@H](C1)[C@H]1C1=C(C#CC)N=NC(C(C(OC)=N2)=CN=C2OC)=C1 ZHHGMIGQLRIYSG-OLZOCXBDSA-N 0.000 description 5
- BMKWBJFWZKSPRC-OCCSQVGLSA-N CN1N=CC(C#CC2=C([C@@H](C3)[C@H]3C(F)F)C=C(C(C(OC)=N3)=CN=C3OC)N=N2)=C1 Chemical compound CN1N=CC(C#CC2=C([C@@H](C3)[C@H]3C(F)F)C=C(C(C(OC)=N3)=CN=C3OC)N=N2)=C1 BMKWBJFWZKSPRC-OCCSQVGLSA-N 0.000 description 5
- NVSBTQBOKJHJMZ-MUWHJKNJSA-N COC1=NC(OC)=NC=C1C(N=N1)=CC([C@@H](C2)[C@H]2C(F)(F)F)=C1Cl Chemical compound COC1=NC(OC)=NC=C1C(N=N1)=CC([C@@H](C2)[C@H]2C(F)(F)F)=C1Cl NVSBTQBOKJHJMZ-MUWHJKNJSA-N 0.000 description 5
- NVNRECZSPMTCKT-RISCZKNCSA-N COC1=NC(OC)=NC=C1C1=CC([C@@H](C2)[C@H]2C(F)(F)F)=C(C#CC2CC2)N=N1 Chemical compound COC1=NC(OC)=NC=C1C1=CC([C@@H](C2)[C@H]2C(F)(F)F)=C(C#CC2CC2)N=N1 NVNRECZSPMTCKT-RISCZKNCSA-N 0.000 description 5
- XOISTSFVMQHDTJ-OCCSQVGLSA-N COC1=NC(OC)=NC=C1C1=CC([C@@H](C2)[C@H]2C(F)F)=C(C#CC2CCC2)N=N1 Chemical compound COC1=NC(OC)=NC=C1C1=CC([C@@H](C2)[C@H]2C(F)F)=C(C#CC2CCC2)N=N1 XOISTSFVMQHDTJ-OCCSQVGLSA-N 0.000 description 5
- NMVLSUAZWKJWIC-OLZOCXBDSA-N COC1=NC(OC)=NC=C1C1=CC([C@@H]2[C@@H](CF)C2)=C(C#CC2CC2)N=N1 Chemical compound COC1=NC(OC)=NC=C1C1=CC([C@@H]2[C@@H](CF)C2)=C(C#CC2CC2)N=N1 NMVLSUAZWKJWIC-OLZOCXBDSA-N 0.000 description 5
- JISBTLVTLVMQKC-WCQYABFASA-N COC1=NC(OC)=NC=C1C1=CC([C@H](C2)[C@@H]2C(F)F)=C(C#CC2CC2)N=N1 Chemical compound COC1=NC(OC)=NC=C1C1=CC([C@H](C2)[C@@H]2C(F)F)=C(C#CC2CC2)N=N1 JISBTLVTLVMQKC-WCQYABFASA-N 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 5
- SCPCAGFRIZEGPK-WUJLRWPWSA-N FC([C@@H](C1)[C@H]1C(C=C(N=N1)Cl)=C1Cl)(F)F Chemical compound FC([C@@H](C1)[C@H]1C(C=C(N=N1)Cl)=C1Cl)(F)F SCPCAGFRIZEGPK-WUJLRWPWSA-N 0.000 description 5
- GSUQLGGYNOVEFG-WUJLRWPWSA-N FC([C@@H](C1)[C@H]1C(C=C(N=N1)Cl)=C1Cl)F Chemical compound FC([C@@H](C1)[C@H]1C(C=C(N=N1)Cl)=C1Cl)F GSUQLGGYNOVEFG-WUJLRWPWSA-N 0.000 description 5
- MERPLFIAKADDAX-UHNVWZDZSA-N FC[C@@H](C1)[C@H]1C(C=C(N=N1)Cl)=C1Cl Chemical compound FC[C@@H](C1)[C@H]1C(C=C(N=N1)Cl)=C1Cl MERPLFIAKADDAX-UHNVWZDZSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- ZPEIVODQHQDOTL-SKDRFNHKSA-N O=C(C(C1=CC([C@@H](C2)[C@H]2C(F)(F)F)=C(C#CC2CC2)N=N1)=CN1)NC1=O Chemical compound O=C(C(C1=CC([C@@H](C2)[C@H]2C(F)(F)F)=C(C#CC2CC2)N=N1)=CN1)NC1=O ZPEIVODQHQDOTL-SKDRFNHKSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- YQPYKYQROJHYBV-SFYZADRCSA-N ethyl (1S,2R)-2-propan-2-ylcyclopropane-1-carboxylate Chemical compound CCOC(=O)[C@H]1C[C@@H]1C(C)C YQPYKYQROJHYBV-SFYZADRCSA-N 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 102000045309 human NT5E Human genes 0.000 description 5
- DOOLFANBWPPEGQ-UHFFFAOYSA-J molybdenum(2+);tetraacetate Chemical compound [Mo+2].[Mo+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O DOOLFANBWPPEGQ-UHFFFAOYSA-J 0.000 description 5
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HBYCKISMJZSUDJ-RITPCOANSA-N (1s,2r)-2-propan-2-ylcyclopropane-1-carboxylic acid Chemical compound CC(C)[C@H]1C[C@@H]1C(O)=O HBYCKISMJZSUDJ-RITPCOANSA-N 0.000 description 4
- LKGKUACPLXCVOF-UHFFFAOYSA-N (2,4-dimethoxypyrimidin-5-yl)boronic acid Chemical compound COC1=NC=C(B(O)O)C(OC)=N1 LKGKUACPLXCVOF-UHFFFAOYSA-N 0.000 description 4
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 101150051188 Adora2a gene Proteins 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- APBFXIQQAWMIQZ-PWSUYJOCSA-N CCC#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(OC)=N2)=CN=C2OC)N=N1 Chemical compound CCC#CC1=C([C@@H](C2)[C@H]2C(F)F)C=C(C(C(OC)=N2)=CN=C2OC)N=N1 APBFXIQQAWMIQZ-PWSUYJOCSA-N 0.000 description 4
- 229940127272 CD73 inhibitor Drugs 0.000 description 4
- HZCQFLMRLKFSEJ-SFYZADRCSA-N COC1=NC(OC)=NC=C1C(N=N1)=CC([C@@H]2[C@@H](CF)C2)=C1Cl Chemical compound COC1=NC(OC)=NC=C1C(N=N1)=CC([C@@H]2[C@@H](CF)C2)=C1Cl HZCQFLMRLKFSEJ-SFYZADRCSA-N 0.000 description 4
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 4
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- AOQBVPPEXCRXAW-RITPCOANSA-N ethyl (1s,2s)-2-(hydroxymethyl)cyclopropane-1-carboxylate Chemical compound CCOC(=O)[C@H]1C[C@@H]1CO AOQBVPPEXCRXAW-RITPCOANSA-N 0.000 description 4
- NPTDXPDGUHAFKC-UHFFFAOYSA-N ethynylcyclopropane Chemical group C#CC1CC1 NPTDXPDGUHAFKC-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 229910001961 silver nitrate Inorganic materials 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910000080 stannane Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- QNYBOILAKBSWFG-SNVBAGLBSA-N (2s)-2-(phenylmethoxymethyl)oxirane Chemical compound C([C@H]1OC1)OCC1=CC=CC=C1 QNYBOILAKBSWFG-SNVBAGLBSA-N 0.000 description 2
- RVWUHFFPEOKYLB-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxidopiperidin-1-ium Chemical compound CC1(C)CCCC(C)(C)[NH+]1[O-] RVWUHFFPEOKYLB-UHFFFAOYSA-N 0.000 description 2
- CEBKHWWANWSNTI-UHFFFAOYSA-N 2-methylbut-3-yn-2-ol Chemical compound CC(C)(O)C#C CEBKHWWANWSNTI-UHFFFAOYSA-N 0.000 description 2
- 101150007969 ADORA1 gene Proteins 0.000 description 2
- 101150046889 ADORA3 gene Proteins 0.000 description 2
- 108050000203 Adenosine receptors Proteins 0.000 description 2
- 102000009346 Adenosine receptors Human genes 0.000 description 2
- 101150078577 Adora2b gene Proteins 0.000 description 2
- RVBKODHIUHPCDT-RQJHMYQMSA-N CC(C)(C)OC([C@@H]1[C@@H](CF)C1)=O Chemical compound CC(C)(C)OC([C@@H]1[C@@H](CF)C1)=O RVBKODHIUHPCDT-RQJHMYQMSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010575 fractional recrystallization Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000004479 myeloid suppressor cell Anatomy 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- KCQJLTOSSVXOCC-UHFFFAOYSA-N tributyl(prop-1-ynyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C#CC KCQJLTOSSVXOCC-UHFFFAOYSA-N 0.000 description 2
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(n-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 1
- IJXJGQCXFSSHNL-UHFFFAOYSA-N 2-amino-2-phenylethanol Chemical compound OCC(N)C1=CC=CC=C1 IJXJGQCXFSSHNL-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- DDTJFSPKEIAZAM-UHFFFAOYSA-N 2-chloro-3-methylbutanoic acid Chemical compound CC(C)C(Cl)C(O)=O DDTJFSPKEIAZAM-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- NQUQLGGUKAKWMS-POYBYMJQSA-N 3-chloro-4-[(1R,2R)-2-(difluoromethyl)cyclopropyl]-6-(2,4-dimethoxypyrimidin-5-yl)pyridazine Chemical compound ClC=1N=NC(=CC=1[C@H]1[C@@H](C1)C(F)F)C=1C(=NC(=NC=1)OC)OC NQUQLGGUKAKWMS-POYBYMJQSA-N 0.000 description 1
- USCSRAJGJYMJFZ-UHFFFAOYSA-N 3-methyl-1-butyne Chemical compound CC(C)C#C USCSRAJGJYMJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RACKOVAPLUVOJA-UHFFFAOYSA-N 4-ethynyl-1-methylpyrazole Chemical compound CN1C=C(C#C)C=N1 RACKOVAPLUVOJA-UHFFFAOYSA-N 0.000 description 1
- IQOAJMSCDHFOGX-SFYZADRCSA-N 5-[5-[(1S,2S)-2-(difluoromethyl)cyclopropyl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC1=NN=C(C=C1[C@H]2C[C@@H]2C(F)F)C3=CNC(=O)NC3=O IQOAJMSCDHFOGX-SFYZADRCSA-N 0.000 description 1
- WHRUIISQCORGKK-KOLCDFICSA-N 5-[6-methyl-5-[(1S,2R)-2-propan-2-ylcyclopropyl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound C(C)(C)[C@@H]1[C@H](C1)C=1C=C(N=NC=1C)C=1C(NC(NC=1)=O)=O WHRUIISQCORGKK-KOLCDFICSA-N 0.000 description 1
- ZUKOCGMVJUXIJA-UHFFFAOYSA-N 6-chlorohex-1-yne Chemical compound ClCCCCC#C ZUKOCGMVJUXIJA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 229940127274 LY-3475070 Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- 101150101087 Nt5e gene Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091007744 Programmed cell death receptors Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- AGVKXDPPPSLISR-UHFFFAOYSA-N n-ethylcyclohexanamine Chemical compound CCNC1CCCCC1 AGVKXDPPPSLISR-UHFFFAOYSA-N 0.000 description 1
- 229940073569 n-methylephedrine Drugs 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000722 protumoral effect Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- QHMQWEPBXSHHLH-UHFFFAOYSA-N sulfur tetrafluoride Chemical compound FS(F)(F)F QHMQWEPBXSHHLH-UHFFFAOYSA-N 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- NFEGNISFSSLEGU-UHFFFAOYSA-N tert-butyl 2-diethoxyphosphorylacetate Chemical compound CCOP(=O)(OCC)CC(=O)OC(C)(C)C NFEGNISFSSLEGU-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a novel compound capable of effectively inhibiting CD73 activity, which is a compound shown in formula I, a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, a preparation method thereof and application thereof in preparing medicines.
Description
PRIORITY INFORMATION
The present application claims priority and benefit from the patent application No. 202011224592.7 filed on 5.11.2020 to the chinese national intellectual property office and is hereby incorporated by reference in its entirety.
Technical Field
The invention belongs to the field of medical chemistry, particularly relates to a pyridazine alkyne compound, and more particularly relates to a pyridazine alkyne compound, a preparation method thereof, and application thereof in preparing medicines.
Background
CD73, also known as extracellular 5' -nucleotidohydrolase, an exonuclease belonging to the metal phosphatase superfamily, is a peripheral glycoprotein, which is anchored in the plasma membrane via Glycosylphosphatidylinositol (GPI), has a molecular weight of 70KD, and is encoded by the NT5E gene. CD73 is widely expressed on the cell surface of various tissues including brain, lung, heart, spleen, lymph nodes, kidney, colon, vascular endothelium and bone marrow; various immune cells are also expressed, including macrophages, neutrophils, myeloid suppressor cells (MDSCs), Dendritic Cells (DCs), natural killer cells (NK), and regulatory T cells (Treg) (Soleimani A et al, Biochimie,2020,176: 21-30.); a variety of tumor cells also have high expression of CD73, such as: melanoma, breast, pancreatic, ovarian, colon, and prostate cancer, among others (Gao Z et al, Biomed Res Int,2014,2014: 460654.). CD73 is also present in soluble form (sCD73) in biological fluids including serum and retains holoenzyme activity.
CD73 exerts a physiological, pathological role primarily by hydrolyzing AMP (adenosine monophosphate) to produce extracellular Adenosine (ADO) via binding to 4G protein-coupled receptors (GPCRs): a1 adenosine receptor (A1AR), A2A adenosine receptor (A2AR), A2B adenosine receptor (A2BR) and A3 adenosine receptor (A3AR), of which A2AR (Linden J et al, Annu. Rev. Immunol.,2019,37: 325-347) play a major role. Adenosine Receptors (ARs) are not only expressed in tumor cells, but also on the cell surface of immune cells and vascular endothelial cells infiltrating in the tumor microenvironment, and ADO, by binding to the receptors, produces a variety of immunosuppressive and tumor-promoting effects.
CD73 is closely associated with tumor growth, angiogenesis and metastasis. Under normal physiological conditions, extracellular ADO levels were between 20 and 300nM, but in the tumor microenvironment, were elevated to maintenance of micromolar levels (30-100 μ M), whereas high extracellular ADO concentrations were primarily affected by CD73 hydrolysis of AMP production. Studies have shown increased levels of soluble CD73(sCD73) in the plasma of cancer patients compared to healthy humans (Klemens M R et al, biochem. biophysis. res. commun.,1990,172: 1371-7.). In gastrointestinal stromal tumors, tumor-infiltrating NK cells express higher levels of CD73, while loss of A2AR signaling in NK cells may improve CD73+Tumor metastasis and enhanced anti-tumor immune responses (Young A et al, Cancer cell.2016; 30(3): 391-403.). CD73 is up-regulated in pancreatic ductal carcinoma (PDAC) compared to normal pancreatic tissue and is associated with tumor size, metastasis and poor prognosis (Harvey Jerry B et al, Front Immunol,2020,11: 508). In preclinical studies by the ORIC company, the CD73 selective inhibitor ORIC-533 significantly reduced ADO concentration in the tumor microenvironment while reducing tumor volume. The results of the studies show that the expression of CD73 is up-regulated in various tumors, and the inhibition of CD73 can possibly reduce the ADO concentration, thereby inhibiting the growth and metastasis of the tumors.
In addition to its single use, CD73 inhibitors can block tumor growth by relieving immunosuppression, and can be used in combination with other targeted therapies and/or immunotherapy, radiation therapy to increase anti-tumor effects. In several tumor models in mice, anti-CD 73 in combination with anti-PD-1/L1 (programmed death receptor 1/ligand 1) and/or anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) antibodies was more effective than treatment with anti-PD-L1 and/or anti-CTLA-4 antibodies alone (Allard B et al, clin. cancer res.,2013,19: 5626-35.); the level of CD73 was found to be upregulated in melanoma patients receiving anti-PD-1 antibody immunotherapy, whereas a unique population of CD 73-highly expressed macrophages persists in glioblastoma patients following anti-PD-1 therapy, and CD73 deficiency enhances the efficacy of anti-PD-1 and anti-CTLA-4 in the mouse glioblastoma model (Goswami S et al, nat. med.,2020,26: 39-46.); radiotherapy causes destruction of a part of tumor cells, releases a large amount of ATP intracellularly to the outside of the cells, and converts it to adenosine under the action of CD73 on the surface of tumor cells or in the form of free ATP, resulting in immunosuppressive effects, which is considered to be one of the causes of poor prognosis after radiotherapy in a part of patients, and thus a synergistic effect may be generated by the combination of a CD73 inhibitor and radiotherapy (Wennerberg E et al, Cancer Immunol Res,2020,8: 465-478.).
Some of the anti-CD 73 mabs (MEDI9447, BMS986179, SRF373/NZV930, CPI-006/CPX-006, TJ004309) and selective small molecule inhibitors (LY3475070, AB680) have now entered clinical stage, with encouraging early outcome (NCT 54027141) in part of clinical trials, and CD73 inhibition may be a promising approach to treat tumors.
Disclosure of Invention
The invention aims to provide a novel CD73 inhibitor which can be used for preparing a medicament for treating tumor-related diseases.
In a first aspect of the present invention, the present invention provides a compound, which is a compound represented by formula I, a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof:
wherein,
m is 0,1, 2,3 or 4;
in R1Independently selected from hydrogen, halogen, hydroxy, cyano, amino, unsubstituted or substituted by RaSubstituted C1-C6Alkyl, or, unsubstituted or substituted by RaSubstituted C1-C6alkyl-O-; the quilt RaSubstituted C1-C6Alkyl, or said RaSubstituted C1-C6In alkyl-O-, the radical is represented by RaThe substitution can be one or more, and R isaEach independently is the following substituent: halogen, hydroxy, cyano, amino, C1-C6Alkyl radical, C1-C6alkyl-O-, -COOH, -C (═ O) NH2(ii) a When the number of the substituents is plural, the substituents may be the same or different; when m is not 0 or 1, R1Independently are the same or different; n is 0,1, 2 or 3;
R2selected from hydrogen, unsubstituted or substituted by RbSubstituted C1-C6Alkyl, unsubstituted or substituted by RbSubstituted C3-C6Cycloalkyl, unsubstituted or substituted by RbSubstituted 5-8 membered aryl, unsubstituted or substituted by RbSubstituted 5-8 membered heteroaryl, unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkyl, or, unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkenyl; the quilt RbSubstituted C1-C6Alkyl, said by RbSubstituted C3-C6Cycloalkyl radicals, said being RbSubstituted 5-8 membered aryl, said substituted RbSubstituted 5-8 membered heteroaryl, said substituted by RbSubstituted 4-8 membered heterocycloalkyl, or said substituted RbIn the substituted 4-8 membered heterocycloalkenyl group, the group represented by RbThe substitution may be one or more, and R isbEach independently is the following substituent: halogen, hydroxy, cyano, amino, carboxy, C3-C6Cycloalkyl radical, C1-C6Alkyl, C substituted by 1-5 identical or different halogens1-C6Alkyl, or, C1-C6alkyl-O-; when the number of the substituents is plural, the substituents may be the same or different;
said unsubstituted or substituted by RbIn the substituted 5-8-membered heteroaryl, the heteroatom is selected from one or more of N, S, O and P, and the number of the heteroatoms is 1-3; said unsubstituted or substituted by RbIn the substituted 4-8 membered heterocyclic alkyl, the heteroatom is selected from one or more of N, S, O and P, and the number of the heteroatom is 1-3; said unsubstituted or substituted by RbIn the substituted 4-8 membered heterocycloalkenyl, the heteroatoms are selected from one or more of N, S, O and P, and the number of the heteroatoms is 1-3.
In a preferred embodiment of the present invention, the compound of formula I, tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug thereof is:
wherein,
m is 0,1, 2,3 or 4;
in R1Independently selected from hydrogen, halogen, hydroxy, cyano, amino, unsubstituted or substituted by RaSubstituted C1-C6Alkyl, or, unsubstituted or substituted by RaSubstituted C1-C6alkyl-O-; the quilt RaSubstituted C1-C6Alkyl, or said RaSubstituted C1-C6In alkyl-O-, the substituents each independently refer to one or more of the following substituents: halogen, hydroxy, cyano, amino, C1-C6Alkyl radical, C1-C6alkyl-O-, -COOH, -C (═ O) NH2(ii) a When the substituent is plural, the substituents are the same or different; when m is not 0 or 1, R1Independently are the same or different;
n is 0,1, 2 or 3;
R2selected from hydrogen, unsubstituted or substituted by RbSubstituted C1-C6Alkyl, unsubstituted or substituted by RbSubstituted C3-C6Cycloalkyl, unsubstituted or substituted by RbSubstituted 5-8 membered aryl, unsubstituted or substituted by RbSubstituted 5-8 membered heteroaryl, unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkyl, or, unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkenyl; the quilt RbSubstituted C1-C6Alkyl, said by RbSubstituted C3-C6Cycloalkyl radicals, said being RbSubstituted 5-8 membered aryl, said substituted RbSubstituted 5-8 membered heteroaryl, said substituted by RbSubstituted 4-8 membered heterocycloalkyl, or said substituted RbIn substituted 4-8 membered heterocycloalkenyl, the substitutions each independently refer to one or more of the following substituents: halogen, hydroxy, cyano, amino, C3-C6Cycloalkyl radical, C1-C6Alkyl, C substituted by 1-5 identical or different halogens1-C6Alkyl, or, C1-C6alkyl-O-; when the number of the substituents is plural, the substituents may be the same or different;
said unsubstituted or substituted by RbIn the substituted 5-8-membered heteroaryl, the heteroatom is selected from one or more of N, S, O and P, and the number of the heteroatoms is 1-3; said unsubstituted or substituted by RbIn the substituted 4-8 membered heterocyclic alkyl, the heteroatom is selected from one or more of N, S, O and P, and the number of the heteroatom is 1-3; said unsubstituted or substituted by RbIn the substituted 4-8 membered heterocycloalkenyl, the heteroatoms are selected from one or more of N, S, O and P, and the number of the heteroatoms is 1-3.
In a preferred embodiment of the invention, when R is2Is unsubstituted or substituted by RbSubstituted C1-C6When alkyl, said C1-C6Alkyl is C1-C4Alkyl, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl.
In a preferred embodiment of the invention, when R is2Is not takenIs substituted or substituted by RbSubstituted C1-C6When it is alkyl, the substituent RbThe number of (a) is 1 to 3, preferably 1.
In a preferred embodiment of the invention, when R is2Is unsubstituted or substituted by RbSubstituted C3-C6Cycloalkyl radical, said C3-C6Cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably cyclopropyl or cyclobutyl.
In a preferred embodiment of the invention, when R is2Is unsubstituted or substituted by RbWhen substituted 5-8 membered aryl, said 5-8 membered aryl is independently phenyl or naphthyl, preferably phenyl.
In a preferred embodiment of the invention, when R is2Is unsubstituted or substituted by RbWhen substituted 5-8 membered heteroaryl, the 5-8 membered heteroaryl is independently pyrrole, pyrazole, triazole, furan, oxazole, thiophene, thiazole, pyridine, pyrazine or pyrimidine, preferably pyrazole, furan, thiophene, pyridine.
In a preferred embodiment of the invention, when R is2Is unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkyl, said 4-8 membered heterocycloalkyl is independently azetidine, oxetane, tetrahydropyrrolyl, tetrahydrofuranyl, hexahydropyran or tetrahydro-2H-thiopyran 1, 1-dioxide, preferably azetidine or oxetane.
In a preferred embodiment of the invention, when R is2Is unsubstituted or substituted by RbWhen substituted with a 4-8 membered heterocycloalkenyl group, the 4-8 membered heterocycloalkenyl group is independently a dihydropyridinyl group, a tetrahydropyridinyl group, a tetrahydropyrimidinyl group, a pyrrolinyl group, an imidazolinyl group, a pyrazolinyl group, a dihydroimidazolyl group, a dihydropyrazolyl group, a dihydrooxazolyl group, a dihydrooxadiazolyl group, a dihydrothiazolyl group, a dihydroisothiazolyl group, a dihydrothienyl group, a dihydropyrrolyl group, a3, 4-dihydro-2H-pyranyl group, a dihydrofuranyl group, a dihydropyrazinyl group, a dihydropyrimidyl group or a fluorodihydrofuranyl group, preferably a1, 2,3, 4-tetrahydropyridinyl group, a1, 2-dihydropyridinyl group, a1, 4-dihydropyridinyl group, a1, 2,3, 6-tetrahydropyridinyl group, a3, 4-dihydro-2H-pyranyl group or a dihydrofuranyl groupA furyl group.
In a preferred embodiment of the invention, RbIs a hydroxyl group.
In a preferred embodiment of the invention, when R isbIs C1-C6When alkyl, said C1-C6Alkyl is C1-C4Alkyl, preferably methyl, ethyl, n-propyl or isopropyl.
In a preferred embodiment of the invention, when R isbWhen the halogen is F, Cl, Br, I, preferably F or Cl.
In a preferred embodiment of the invention, when R is1When halogen is used, the halogen is F, Cl, Br or I, preferably F or Cl.
In a preferred embodiment of the invention, when R is1When it is halogen, m is 0,1 or 2.
In a preferred embodiment of the invention, when R is1Is unsubstituted or substituted by RaSubstituted C1-C6Alkyl, or, unsubstituted or substituted by RaSubstituted C1-C6alkyl-O-said C1-C6Alkyl is independently C1-C4Alkyl, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl.
In a preferred embodiment of the invention, when R is1Is unsubstituted or substituted by RaSubstituted C1-C6Alkyl, or, unsubstituted or substituted by RaSubstituted C1-C6When alkyl-O-, m is 1 or 2, preferably m is 1.
In bookIn a preferred embodiment of the invention, when R is1Is as a quilt RaSubstituted C1-C6Alkyl, or, by RaSubstituted C1-C6In the case of alkyl-O-, the number of said substitution is independently 1 to 3, preferably 2.
In a preferred embodiment of the invention, when R is1Is as a quilt RaSubstituted C1-C6Alkyl, or, by RaSubstituted C1-C6When alkyl-O-, the substituents are each independently C1-C6Alkyl, or C1-C6alkyl-O-, C as described for said substitution1-C6Alkyl is independently C1-C4Alkyl, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl.
In a preferred embodiment of the invention, when R isaWhen halogen is used, the halogen is F, Cl, Br or I, preferably F or Cl.
In a preferred embodiment of the present invention, whenIs composed ofWhen is in use, theIs composed of
In a preferred embodiment of the present invention, whenIs composed ofWhen is in use, theIs composed of
In a preferred embodiment of the present invention, whenIs composed ofWhen is in use, theIs composed of
In a preferred embodiment of the present invention, whenIs composed ofWhen is in use, theIs composed of
In a preferred embodiment of the present invention, the compound represented by formula I, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug is:
wherein,
R1independently selected from hydrogen, halogen, hydroxy, cyano, amino, unsubstituted or substituted by RaSubstituted C1-C6Alkyl, or, unsubstituted or substituted by RaSubstituted C1-C6alkyl-O-; the quilt RaSubstituted C1-C6Alkyl, or said RaSubstituted C1-C6In alkyl-O-, the substituents each independently refer to one or more of the following substituents: halogen, hydroxy, cyano, amino, C1-C6Alkyl radical, C1-C6alkyl-O-, -COOH, -C (═ O) NH2(ii) a When the number of the substituents is plural, the substituents may be the same or different;
R2selected from hydrogen, unsubstituted or substituted by RbSubstituted C1-C6Alkyl, unsubstituted or substituted by RbSubstituted C3-C6Cycloalkyl, unsubstituted or substituted by RbSubstituted 5-8 membered aryl, unsubstituted or substituted by RbSubstituted 5-8 membered heteroaryl, unsubstituted or substituted by RbSubstituted 4-8 membered heterocyclic ringsAlkyl, or, unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkenyl; the quilt RbSubstituted C1-C6Alkyl, said by RbSubstituted C3-C6Cycloalkyl radicals, said being RbSubstituted 5-8 membered aryl, said substituted by RbSubstituted 5-8 membered heteroaryl, said substituted by RbSubstituted 4-8 membered heterocycloalkyl, or said substituted RbIn substituted 4-8 membered heterocycloalkenyl, the substitutions each independently refer to one or more of the following substituents: halogen, hydroxy, cyano, amino, C3-C6Cycloalkyl radical, C1-C6Alkyl, C substituted by 1-5 identical or different halogens1-C6Alkyl, or, C1-C6alkyl-O-; when the number of the substituents is plural, the substituents may be the same or different;
said unsubstituted or substituted by RbIn the substituted 5-8-membered heteroaryl, the heteroatom is selected from one or more of N, S, O and P, and the number of the heteroatoms is 1-3; said unsubstituted or substituted by RbIn the substituted 4-8 membered heterocyclic alkyl, the heteroatom is selected from one or more of N, S, O and P, and the number of the heteroatom is 1-3; said unsubstituted or substituted by RbIn the substituted 4-8 membered heterocycloalkenyl, the heteroatoms are selected from one or more of N, S, O and P, and the number of the heteroatoms is 1-3.
In a preferred embodiment of the present invention, the compound represented by formula I, the hydrate, the solvate, the pharmaceutically acceptable salt or the prodrug thereof isWherein R is1And R2Having the definitions as previously described.
In a preferred embodiment of the invention, R1Selected from difluoromethyl, trifluoromethyl, dichloromethyl, trichloromethyl or isopropyl; r2Selected from methyl, ethyl or cyclopropyl.
In a preferred embodiment of the present invention, the compound according to formula I, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug is selected from any one of the following compounds:
in a second aspect of the present invention, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of the above compound, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, and a pharmaceutically acceptable excipient.
According to a specific embodiment of the present invention, the pharmaceutical composition of the present invention may include a therapeutically effective amount of the above-mentioned compound, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, and a pharmaceutically acceptable carrier, diluent or excipient mixed to prepare a pharmaceutical preparation suitable for oral or parenteral administration. Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, and oral routes. The formulations may be administered by any route, for example by infusion or bolus injection, by a route of absorption through epithelial or cutaneous mucosa (e.g. oral mucosa or rectum, etc.). Administration may be systemic or local. Examples of the formulation for oral administration include solid or liquid dosage forms, specifically, tablets, pills, granules, powders, capsules, syrups, emulsions, suspensions and the like. The formulations may be prepared by methods known in the art and include carriers, diluents or excipients conventionally used in the art of pharmaceutical formulation.
In a third aspect of the invention, the invention provides the use of the above compound, or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug thereof, pharmaceutical composition in combination with PD-1 antibody, PD-L1 antibody, CTLA-4 antibody or PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor for the manufacture of a medicament for the treatment of CD 73-associated diseases, which medicament is useful for the treatment of cancer. These cancers include, for example, bladder cancer, breast cancer, cholangiocarcinoma, rectal cancer, colon cancer, stomach cancer, gallbladder cancer, glioblastoma, head and neck cancer, liver cancer, lung cancer, lymphoma, medulloblastoma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, or renal cancer.
In a fourth aspect of the present invention, the present invention provides the use of the above compound, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, or the above pharmaceutical composition in the preparation of a medicament for treating diseases related to CD 73.
According to a specific embodiment of the invention, the compound or the tautomer, the stereoisomer, the hydrate, the solvate, the pharmaceutically acceptable salt or the prodrug thereof or the pharmaceutical composition is used for preparing a medicament for treating CD73 related diseases, and the medicament can be used for treating cancers. These cancers include, for example, bladder cancer, breast cancer, cholangiocarcinoma, colorectal cancer, colon cancer, gastric cancer, gallbladder cancer, glioblastoma, head and neck cancer, liver cancer, lung cancer, lymphoma, medulloblastoma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, or renal cancer.
Terms and definitions
Unless otherwise indicated, the terms and definitions used in the present application, including in the specification and claims of the present application, are as follows.
It will be understood by those skilled in the art that, according to the convention used in the art, in the structural formulae of the present application,for delineating chemical bonds, which are the points at which moieties or substituents are attached to a core structure or a backbone structure.
The term "pharmaceutically acceptable" is intended to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The term "pharmaceutically acceptable salts" refers to pharmaceutically acceptable salts of non-toxic acids or bases, including salts of inorganic acids and bases, organic acids and bases.
In addition to pharmaceutically acceptable salts, other salts are also contemplated by the present invention. They may serve as intermediates in the purification of the compounds or in the preparation of other pharmaceutically acceptable salts or may be used in the identification, characterization or purification of the compounds of the invention.
The term "pharmaceutical composition" denotes a mixture of one or more compounds described herein or a physiologically/pharmaceutically acceptable salt or prodrug thereof with other chemical components, such as physiologically/pharmaceutically acceptable carriers and excipients. The purpose of the pharmaceutical composition is to facilitate the administration of the compound to an organism.
The term "adjuvant" refers to a pharmaceutically acceptable inert ingredient. Examples of classes of the term "excipient" include, without limitation, binders, disintegrants, lubricants, glidants, stabilizers, fillers, diluents, and the like. Excipients enhance the handling characteristics of the pharmaceutical formulation, i.e., make the formulation more amenable to direct compression by increasing flowability and/or cohesiveness.
The term "prodrug" refers to a compound of the invention that can be converted to a biologically active compound under physiological conditions or by solvolysis. Prodrugs of the invention are prepared by modifying functional groups in the compounds, which modifications may be routinely made or removed in vivo to give the parent compound. Prodrugs include compounds of the present invention wherein a hydroxy or amino group is attached to any group that, when administered to a mammalian subject, cleaves to form a free hydroxy or a free amino group, respectively.
The term "stereoisomer" refers to isomers resulting from the different arrangement of atoms in a molecule, including cis-trans isomers, enantiomers, diastereomers, and conformers.
Depending on the choice of starting materials and process, the compounds according to the invention may be present as one of the possible isomers or as a mixture thereof, for example as pure optical isomers, or as a mixture of isomers, for example as racemic and diastereomeric mixtures, depending on the number of asymmetric carbon atoms. When describing optically active compounds, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule with respect to the chiral center (or centers) in the molecule. The prefixes D and L or (+) and (-) are the symbols used to specify the rotation of plane polarized light by the compound, where (-) or L indicates that the compound is left-handed. Compounds prefixed with (+) or D are dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. A particular stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often referred to as a mixture of enantiomers. A 50:50 mixture of enantiomers is referred to as a racemic mixture or racemate, which may occur when there is no stereoselectivity or stereospecificity in the chemical reaction or process. Many geometric isomers of olefins, C ═ N double bonds, and the like, may also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. When compounds described herein contain olefinic double bonds, such double bonds include both E and Z geometric isomers, unless otherwise specified. If the compound contains a disubstituted cycloalkyl group, the substituents of the cycloalkyl group may be in the cis or trans (cis-or trans-) configuration.
When bonds to chiral carbons in the formulae of the present invention are depicted as straight lines, it is to be understood that both the (R) and (S) configurations of the chiral carbons and their enantiomerically pure compounds and mixtures resulting therefrom are included within the scope of this formula. The enantiomers or enantiomerically pure compounds herein are illustrated by Maehr, J.chem.Ed.1985, 62: 114-120. Unless otherwise indicated, the absolute configuration of a stereocenter is indicated by wedge bonds and dashed bonds.
Optically active (R) -or (S) -isomers can be prepared using chiral synthons or chiral preparations, or resolved using conventional techniques. The compounds of the present invention containing asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Resolution of racemic mixtures of compounds can be carried out by any of a number of methods known in the art. Exemplary methods include fractional recrystallization using chiral resolving acids, which are optically active salt-forming organic acids. Suitable resolving agents for use in the fractional recrystallization process are, for example, the D and L forms of optically active acids, such as tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or various optically active camphorsulfonic acids, such as β -camphorsulfonic acid. Other resolving agents suitable for fractional crystallization processes include stereoisomerically pure forms of α -methyl-benzylamine (e.g., S and R forms or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1, 2-diaminocyclohexane, and the like. Resolution of the racemic mixture can also be carried out by elution on a chromatographic column packed with an optically active resolving agent (e.g. dinitrobenzoylphenylglycine). The method can be performed by High Performance Liquid Chromatography (HPLC) or Supercritical Fluid Chromatography (SFC). The choice of the particular method and the conditions of elution, the choice of the chromatography column can be selected by the person skilled in the art according to the structure of the compound and the results of the test. Further, any enantiomer or diastereomer of the compounds described herein may also be obtained by stereoorganic synthesis using optically pure starting materials or reagents of known configuration.
The term "tautomer" refers to an isomer of a functional group resulting from the rapid movement of an atom in two positions in a molecule. The compounds of the invention may exhibit tautomerism. Tautomeric compounds may exist in two or more interconvertible species. Prototropic tautomers result from the migration of a covalently bonded hydrogen atom between two atoms. Tautomers generally exist in equilibrium, and attempts to isolate a single tautomer often result in a mixture whose physicochemical properties are consistent with the mixture of compounds. The position of equilibrium depends on the chemical properties within the molecule. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the keto form predominates; whereas in phenol the enol type predominates. The present invention encompasses all tautomeric forms of the compounds.
The compounds of the invention may be present in one or more of the constituent partsThe atoms of the compounds contain unnatural proportions of atomic isotopes. For example, the compounds may be labelled with radioisotopes, such as deuterium (g) ((R))2H) Tritium (A)3H) Iodine-125 (125I) Or C-14(14C) In that respect All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
The term "effective amount" or "therapeutically effective amount" with respect to a drug or pharmacologically active agent refers to a sufficient amount of the drug or agent that is non-toxic but achieves the desired effect. For oral dosage forms of the invention, an "effective amount" of one active agent in a composition is the amount required to achieve the desired effect when combined with another active agent in the composition. The determination of an effective amount varies from person to person, depending on the age and general condition of the recipient and also on the particular active substance, and an appropriate effective amount in an individual case can be determined by a person skilled in the art according to routine tests.
The terms "active ingredient," "therapeutic agent," "active substance," or "active agent" refer to a chemical entity that is effective in treating a target disorder, disease, or condition.
The term "substituted" means that any one or more hydrogen atoms on a particular atom is replaced with a substituent, including deuterium and hydrogen variants, so long as the valency of the particular atom is normal and the substituted compound is stable. When the substituent is a keto group (i.e., ═ O), it means that two hydrogen atoms are substituted. The keto substitution does not occur on the aromatic group. The term "optionally substituted" means that it may or may not be substituted, and unless otherwise specified, the kind and number of substituents may be arbitrary on the basis of chemical realizability.
The term "C1-C6Alkyl "is understood to mean a straight-chain or branched, saturated monovalent hydrocarbon radical having 1,2,3,4, 5 or 6 carbon atoms. Alkyl is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-ethylpropyl, 1, 2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3-dimethylbutyl, 2-dimethylbutyl, 1-dimethylbutyl, 2, 3-dimethylbutyl, 1, 3-dimethylbutyl or 1, 2-dimethylbutyl and the like or isomers thereof. In particular, the radicals have 1,2 or 3 carbon atoms ("C)1-C3Alkyl groups) such as methyl, ethyl, n-propyl or isopropyl.
The term "C1-C6alkyl-O- "is understood to mean that the alkyl radical is bonded to the rest of the molecule via an oxygen atom, where" C "is1-C6Alkyl "has the above definition. Such as methyl-O-, ethyl-O-.
The term "C3-C6Cycloalkyl "is understood to mean a saturated monovalent monocyclic or bicyclic hydrocarbon ring having 3 to 6 carbon atoms, including fused or bridged polycyclic ring systems. Such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
The term "4-8 membered heterocyclyl" or "4-8 membered heterocycloalkyl" is understood to mean a saturated, unsaturated or partially saturated monocyclic, bicyclic or tricyclic ring having 4 to 8 atoms, wherein 1,2,3,4 or 5 ring atoms are selected from N, O and S, which may be connected through carbon or nitrogen, unless otherwise indicated, wherein-CH is2-The group is optionally replaced by-C (O) -; and wherein unless otherwise stated to the contrary, the ring nitrogen atom or the ring sulfur atom is optionally oxidized to form an N-oxide or S-oxide or the ring nitrogen atom is optionally quaternized; wherein-NH in the ring is optionally substituted with acetyl, formyl, methyl or methanesulfonyl; and the ring is optionally substituted with one or more halogens. It is understood that when the total number of S and O atoms in the heterocyclic group exceeds 1, these heteroatoms are not adjacent to each other. If the heterocyclyl is bicyclic or tricyclic, at least one ring may optionally be a heteroaromatic ring or an aromatic ring, provided that at least one ring is non-heteroaromatic. If the heterocyclic group is monocyclic, it is not necessarily aromatic. Examples of heterocyclyl groups include, but are not limited to, piperidinyl, N-acetylpiperidinyl, N-methylpiperidinyl, N-formylpiperazinyl, N-methylsulfonylpiperazinyl, homopiperazinyl, piperazinyl, azetidinyl, piperidinyl, piperazinyl, and the like,Oxetanyl, morpholinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, indolinyl, tetrahydropyranyl, dihydro-2H-pyranyl, tetrahydrofuranyl, tetrahydrothiopyranyl-1-oxide, tetrahydrothiopyranyl-1, 1-dioxide, 1H-pyridin-2-one, and 2, 5-dioxoimidazolidinyl.
The term "4-8 membered heterocycloalkenyl" is to be understood as a non-aromatic mono-or polycyclic group containing 4 to 8 ring atoms, preferably 5 to 6 ring atoms, wherein the 4-8 membered heterocycloalkenyl comprises 1 to 3 heteroatoms selected from N, O, S and P and contains at least one carbon-carbon double bond or carbon-nitrogen double bond. An aza, oxa or thia comprised in the group name means that at least one nitrogen, oxygen or sulfur atom respectively is a ring atom. The nitrogen or sulfur atom of the 4-8 membered heterocycloalkenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S-dioxide. Preferred 4-8 membered heterocycloalkenyl groups include, but are not limited to, 1,2,3, 4-tetrahydropyridyl, 1, 2-dihydropyridyl, 1, 4-dihydropyridyl, 1,2,3, 6-tetrahydropyridyl, 1,4,5, 6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydrooxazolyl, dihydrooxadiazolyl, dihydrothiazolyl, 3, 4-dihydro-2H-pyranyl, dihydrofuranyl, fluorodihydrofuranyl, oxides thereof, and the like. "4-8 membered heterocycloalkenyl" may also include two available hydrogen atoms on the same carbon atom of the ring simultaneously substituted with a single group ═ O (i.e., to form a carbonyl group).
The term "5-to 8-membered aryl" is to be understood as meaning a mono-, bi-or tricyclic hydrocarbon ring having a monovalent or partial aromaticity of 5 to 8 carbon atoms, in particular a ring having 6 carbon atoms ("C6Aryl "), such as phenyl; when the 5-to 8-membered aryl group is substituted, it may be mono-or poly-substituted. And, the substitution site thereof is not limited, and may be, for example, ortho-, para-or meta-substitution.
The term "5-8 membered heteroaryl" is to be understood as a monovalent monocyclic, bicyclic or tricyclic aromatic ring group having 5-8 ring atoms, in particular 5 or 6 carbon atoms, and comprising 1-5 heteroatoms independently selected from N, O and S. Preferably 1 to 3 and independently selected from N, O and S, and further may be benzo-fused in each case. In particular, heteroaryl is selected from thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl and the like; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and the like.
The term "halo" or "halogen" is fluorine, chlorine, bromine and iodine.
In addition, it should be noted that, unless otherwise explicitly indicated, the recitation of "… … independently" as used herein is to be understood in a broad sense to mean that each individual species so described is independent of the other and may be the same or different specific groups. In more detail, the expression "… … independently" can mean that the specific options expressed between the same symbols do not affect each other in different groups, or that the specific options expressed between the same symbols do not affect each other in the same groups.
Advantageous effects
According to the embodiment of the invention, the CD73 inhibitor which has a novel structure, excellent pharmacokinetic property and good drug effect or drug success rate is provided, and can be used for effectively treating CD73 related diseases and symptoms.
The compound of the invention has good inhibition effect on CD73 enzyme and good in vitro drug effect. In addition, mouse experiment results show that the compound of the invention has excellent pharmacokinetic properties and good drug forming property.
In addition, the compound of the invention has obvious effect of inhibiting the growth of CT-26 colorectal cancer and E.G7-OVAT cell lymphoma by being used alone or being used together with PD-1/L1 antibody.
Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Detailed Description
The scheme of the invention will be explained with reference to the examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the invention only and should not be taken as limiting the scope of the invention. The examples, where specific techniques or conditions are not indicated, are to be construed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
Unless otherwise specified, the compounds of the present invention are structurally defined by Nuclear Magnetic Resonance (NMR) and/or Mass Spectrometry (MS). NMR shift in units of 10-6(ppm). Solvents for NMR measurement were deuterated dimethyl sulfoxide, deuterated chloroform, deuterated methanol, etc., and an internal standard was Tetramethylsilane (TMS).
Abbreviations of the present invention are defined as follows:
m: molar concentration, e.g. 1M hydrochloric acid for 1mol/L hydrochloric acid solution
DCM: methylene dichloride
DMP: dess-martin oxidizer
DMF N, N-dimethylformamide
DAST: diethylaminosulfur trifluoride
DMSO, DMSO: dimethyl sulfoxide
A dioxane: 1, 4-dioxane
TEA: triethylamine
THF: tetrahydrofuran (THF)
TEMPO: 2,2,6, 6-tetramethylpiperidine oxide
LC-MS: liquid chromatography-mass spectrometry
IC50: the median inhibitory concentration is the concentration at which half of the maximal inhibitory effect is achieved.
Comparative example 1: preparation of Positive control Compound 1
5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6-methylpyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (control Compound 1)
Reference is made to the process of patent WO2019168744 Al.
1H NMR(400MHz,DMSO-d6)δ11.51(s,2H),8.27(s,1H),7.77(s,1H),6.17-5.85(m,1H),2.69(s,3H),2.32-2.29(m,1H),1.77-1.70(m,1H),1.32-1.18(m,2H).
LC-MS,M/Z(ESI):295.0[M+H]+。
The "control Compound 1" mentioned below refers to the compound described in comparative example 1.
Comparative example 2: preparation of Positive control Compound 2
5- (5- ((1S,2R) -2-isopropylcyclopropyl) -6-methylpyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (control Compound 2)
Reference is made to the process of patent WO2019168744 Al.
1H NMR(400MHz,CD3OD)δ8.65(s,1H),8.22(s,1H),2.89(s,3H),2.07-2.10(m,1H),1.33-1.45(m,4H),1.10(d,6H).
LC-MS,M/Z(ESI):287.0[M+H]+。
The "control Compound 2" mentioned below refers to the compound described in comparative example 2.
Preparation 1: preparation of intermediate A
3-chloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (intermediate A)
The synthetic route for intermediate a is shown below:
the first step is as follows: synthesis of ethyl (1S,2S) -2- ((benzyloxy) methyl) cyclopropane-1-carboxylate (A-3)
Sodium hydride (58.5g, 1.46mol, content 60%) was suspended in toluene (3000mL) under nitrogen, triethyl phosphonoacetate (327.7g, 1.46mol) was added dropwise at 0 ℃ and stirred at 25 ℃ for 1 hour after completion of the addition, and then (S) - (+) -glycidyl benzyl ether (200g, 1.22mol) was added to the reaction mixture and the temperature was raised to 130 ℃ for reaction for 12 hours. The reaction mixture was diluted with water (5000mL), then extracted with ethyl acetate (2000 mL. times.2), the organic layers were combined, the organic layer was washed with saturated brine (2000mL), dried over sodium sulfate, and concentrated to give the crude product. Separation and purification with silica gel column (petroleum ether: ethyl acetate (V/V) ═ 50:1-10:1, gradient elution) gave ethyl (1S,2S) -2- ((benzyloxy) methyl) cyclopropane-1-carboxylate (a-3) as a red oil (180g, 63% yield).
1H NMR(400MHz,CDCl3)δ7.18-7.25(m,5H),4.42(s,2H),4.00-4.04(m,2H),3.33-3.37(m,1H),3.24-3.28(m,1H),1.62-1.66(m,1H),1.46-1.49(m,1H),1.06-1.16(m,4H),0.75-0.78(m,1H).
The second step is that: synthesis of ethyl (1S,2S) -2- (hydroxymethyl) cyclopropane-1-carboxylate (A-4)
Ethyl (1S,2S) -2- ((benzyloxy) methyl) cyclopropane-1-carboxylate (A-3) (120g, 512.2mmol) was dissolved in ethanol (1200mL), and palladium on carbon (30.0g, content 10%) was added under nitrogen protection, followed by substitution 3 times with hydrogen gas and reaction at 50Psi pressure for 24 hours. Cooled to room temperature, filtered through celite to remove palladium on carbon, the filter cake was washed 3 times with ethanol, and the filtrate was concentrated to give (1S,2S) -ethyl 2- (hydroxymethyl) cyclopropane-1-carboxylate (a-4) as a yellow oil (65.0g, 85% yield).
The third step: synthesis of ethyl (1S,2S) -2-formylcyclopropane-1-carboxylate (A-5)
Ethyl (1S,2S) -2- (hydroxymethyl) cyclopropane-1-carboxylate (A-4) (100g, 693.6mmol) was dissolved in dichloromethane (1500mL), and dess-martin oxidant (353.0g, 832.4mmol) was added slowly at 0 ℃ and then reacted at 25 ℃ for 12 hours. After completion of the reaction, the reaction solution was poured into an aqueous sodium carbonate solution (500mL) and an aqueous sodium sulfite solution (500mL), followed by extraction with methylene chloride (2000 mL. times.2), and the organic phases were combined, washed with a saturated saline solution (500mL), dried over sodium sulfate, filtered, and concentrated to give ethyl (1S,2S) -2-formylcyclopropane-1-carboxylate (A-5) as a yellow oil (67.0g, yield 68%).
1H NMR(400MHz,CDCl3)δ9.31(d,1H),4.18(q,2H),2.40-2.46(m,1H),2.24-2.28(m,1H),1.59-1.64(m,1H),1.50-1.54(m,1H),1.35-1.20(m,3H).
The fourth step: synthesis of ethyl (1S,2S) -2- (difluoromethyl) cyclopropane-1-carboxylate (A-6)
Ethyl (1S,2S) -2-formylcyclopropane-1-carboxylate (A-5) (95g, 668.3mmol) was dissolved in methylene chloride (1200mL), and diethylaminosulfur trifluoride (237.0g, 194mL, 1.47mol) was added dropwise at 0 ℃ and the reaction was stirred at 25 ℃ for 2 hours. The reaction mixture was quenched with saturated aqueous sodium bicarbonate (1000mL) and then extracted with dichloromethane (500mL × 2), the organic layers were combined, the organic phase was washed with saturated brine (1000mL), dried over sodium sulfate, and concentrated to give ethyl (1S,2S) -2- (difluoromethyl) cyclopropane-1-carboxylate (a-6) (95g, crude) as a yellow oil which was used directly in the next step.
1H NMR(400MHz,CDCl3)δ5.62-5.91(m,1H),4.16(q,2H),1.88-1.96(m,2H),1.26-1.30(m,4H),1.12-1.16(m,1H).
The fifth step: synthesis of (1S,2S) -2- (difluoromethyl) cyclopropane-1-carboxylic acid (A-7)
Ethyl (1S,2S) -2- (difluoromethyl) cyclopropane-1-carboxylate (A-6) (95.0g, 578.7mmol) was dissolved in methanol (500mL) and water (100mL), followed by addition of sodium hydroxide (69.5g, 1.74mmol) and reaction at 25 ℃ for 12 hours. After completion of the reaction, the reaction mixture was concentrated, water (500mL) was added, extraction was performed with methyl t-butyl ether (500mL × 2), the aqueous phase was collected, the pH of the aqueous phase was adjusted to 3 with 1M hydrochloric acid, followed by extraction with ethyl acetate (500mL × 3), the organic phases were combined, washed with saturated brine (500mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give (1S,2S) -2- (difluoromethyl) cyclopropane-1-carboxylic acid (a-7) (47.0g, yield 60%) as a yellow oil.
1H NMR(400MHz,CDCl3)δ9.52(br.s,1H),5.65-5.94(m,1H),1.89-1.94(m,2H),1.34-1.37(m,1H),1.23-1.27(m,1H).
And a sixth step: synthesis of 3, 6-dichloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) pyridazine (A-9)
3, 6-dichloropyridazine (6.60g, 44.3mmol) and (1S,2S) -2- (difluoromethyl) cyclopropane-1-carboxylic acid (6.03g, 44.3mmol) were dissolved in water (150mL), concentrated sulfuric acid (6.74mL) was added, and the temperature was raised to 70 ℃ under nitrogen. Then, an aqueous solution of silver nitrate (4.20g, 24.7mmol, 7.5mL) was added rapidly, and then an aqueous solution of ammonium persulfate (30.3g, 132.9mmol, 75mL) was added slowly dropwise, and the reaction was continued at 70 ℃ for 2 hours. The reaction solution was adjusted to pH 9 with aqueous ammonia, followed by extraction with ethyl acetate (500 mL. times.2), and the organic layers were combined, and the organic phase was washed with saturated brine (500mL), dried over sodium sulfate, and concentrated to give a crude product. Purification by silica gel column separation (petroleum ether: ethyl acetate (V/V) ═ 20:1-3:1, gradient elution) afforded 3, 6-dichloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) pyridazine (a-9) as a yellow oil (5.00g, 46.4% yield).
1H NMR(400MHz,CDCl3)δ7.10(s,1H),5.79-6.08(m,1H),2.39-2.45(m,1H),1.68-1.75(m,1H),1.51-1.54(m,1H),1.22-1.25(m,1H).
LC-MS,M/Z(ESI):239.1[M+H]+。
The seventh step: synthesis of 3-chloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (A)
3, 6-dichloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) pyridazine (5.00g, 20.9mmol) and 2, 4-dimethoxypyrimidine-5-boronic acid (3.85g, 20.9mmol) were dissolved in 1, 4-dioxane (50mL) and water (10mL), sodium carbonate (6.65g, 62.7mmol) and [1, 1-bis (diphenylphosphino) ferrocene ] dichloropalladium (1.53g, 2.09mmol) were added under nitrogen, and the mixture was heated to 70 ℃ for 1 hour. The reaction mixture was diluted with water (50mL) and extracted with ethyl acetate (100 mL. times.3), the organic phases were combined, the organic phase was washed with saturated brine (100mL), dried over sodium sulfate and concentrated to give the crude product. Separation and purification on silica gel column (petroleum ether: ethyl acetate (V/V) ═ 10:1-2:1, gradient elution) gave 3-chloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (a) as a yellow oil (4.5g, 48% yield).
LC-MS,M/Z(ESI):343.1[M+H]+。
Preparation 2: preparation of intermediate B
3-chloro-6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazine (intermediate B)
The synthetic route of intermediate B is shown below:
the first step is as follows: synthesis of tert-butyl (1S,2S) -2- ((benzyloxy) methyl) cyclopropane-1-carboxylate (B-3)
Sodium hydride (14.6g, 365.4mmol, content 60%) was suspended in toluene (500mL) under nitrogen, followed by dropwise addition of tert-butyl diethylphosphonoacetate (92.2g, 365.4mmol), stirring at 25 ℃ for 30 minutes after completion of the addition, and then (S) - (+) -glycidyl benzyl ether (50.0g, 304.5mmol) was added to the reaction mixture, and the temperature was raised to 130 ℃ for reaction for 8 hours. The reaction mixture was diluted with water (100mL) and extracted with ethyl acetate (100 mL. times.2), the organic layers were combined, the organic phase was washed with saturated brine (50mL), dried over sodium sulfate, and concentrated to give the crude product. Separation and purification by silica gel column (petroleum ether: ethyl acetate (V/V) ═ 50:1-10:1, gradient elution) gave the compound tert-butyl (1S,2S) -2- ((benzyloxy) methyl) cyclopropane-1-carboxylate (B-3) as a yellow oil (55g, yield 68.8%).
The second step is that: synthesis of tert-butyl (1S,2S) -2- (hydroxymethyl) cyclopropane-1-carboxylate (B-4)
Tert-butyl (1S,2S) -2- ((benzyloxy) methyl) cyclopropane-1-carboxylate (B-3) (55g, 209.6mmol) was dissolved in ethanol (500mL), palladium on carbon (20.0g, content 10%) was added under nitrogen protection, followed by substitution 3 times with hydrogen gas and reaction at 50 ℃ for 24 hours under a pressure of 50 Psi. After cooling to room temperature, palladium on carbon was removed by filtration through celite, the cake was washed 3 times with ethanol, and the filtrate was concentrated to give (1S,2S) -tert-butyl 2- (hydroxymethyl) cyclopropane-1-carboxylate (B-4) (36.0g, yield 99.7%) as a yellow oil.
1H NMR(400MHz,CDCl3)δ3.50–3.63(m,2H),1.67–1.72(m,1H),1.47(s,9H),1.38(t,1H),1.14–1.89(m,1H),0.78-0.84(m,1H)。
The third step: synthesis of tert-butyl (1S,2S) -2- (fluoromethyl) cyclopropane-1-carboxylate (B-5)
Tert-butyl (1S,2S) -2- (hydroxymethyl) cyclopropane-1-carboxylate (B-4) (2.5g, 14.5mmol) was dissolved in methylene chloride (25mL), diethylaminosulfur trifluoride (4.68g, 3.84mL, 29.0mmol) was added dropwise at 0 ℃ and the reaction was stirred at 0 ℃ for 1 hour. The reaction mixture was quenched with saturated aqueous sodium bicarbonate (100mL) and then extracted with dichloromethane (100 mL. times.2), the organic layers were combined, the organic phase was washed with saturated brine (50mL), dried over sodium sulfate, and concentrated to give the crude product. Separation and purification by silica gel column (petroleum ether: ethyl acetate (V/V) ═ 50:1-10:1, gradient elution) gave (1S,2S) -2- (fluoromethyl) cyclopropane-1-carboxylic acid tert-butyl ester (B-5) as a yellow oil (2.0g, yield 79%).
1H NMR(400MHz,CDCl3)δ4.19-4.42(m,2H),1.75–1.82(m,1H),1.55-1.59(m,1H),1.46(s,9H),1.18–1.23(m,1H),0.83-0.88(m,1H)。
The fourth step: synthesis of (1S,2S) -2- (fluoromethyl) cyclopropane-1-carboxylic acid (B-6)
Tert-butyl (1S,2S) -2- (fluoromethyl) cyclopropane-1-carboxylate (B-5) (2.0g, 11.5mmol) was dissolved in a solution of hydrogen chloride (4M) in 1, 4-dioxane (10mL), and the mixture was stirred at 20 ℃ for 1 hour. The reaction was concentrated to give (1S,2S) -2- (fluoromethyl) cyclopropane-1-carboxylic acid (B-6) (1.3g, 95% yield) as a yellow oil.
1H NMR(400MHz,CDCl3)δ4.16-4.52(m,2H),1.88-1.94(m,1H),1.67-1.71(m,1H),1.34–1.37(m,1H),1.01-1.05(m,1H)。
The fifth step: synthesis of 3, 6-dichloro-4- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazine (B-8)
3, 6-dichloropyridazine (630mg, 4.23mmol) and (1S,2S) -2- (fluoromethyl) cyclopropane-1-carboxylic acid (B-6) (500mg, 4.23mmol) were dissolved in water, concentrated sulfuric acid (0.5mL) was added, and the temperature was raised to 70 ℃ under nitrogen. Then, an aqueous solution of silver nitrate (359.6mg, 2.12mmol, 5mL) was added rapidly, and then an aqueous solution of ammonium persulfate (2.90g, 12.7mmol, 10mL) was added slowly dropwise, and the reaction was continued at 70 ℃ for 1 hour. The reaction solution was adjusted to pH 9 with aqueous ammonia, followed by extraction with ethyl acetate (100 mL. times.2), and the organic layers were combined, and the organic phase was washed with saturated brine (50mL), dried over sodium sulfate, and concentrated to give a crude product. Purification by silica gel column separation (petroleum ether: ethyl acetate (V/V) ═ 10:1-3:1, gradient elution) gave 3, 6-dichloro-4- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazine (B-8) as a yellow oil (500mg, yield 26%).
And a sixth step: synthesis of 3-chloro-6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazine (B)
3, 6-dichloro-4- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazine (300mg, 1.36mmol) and 2, 4-dimethoxypyrimidine-5-boronic acid were dissolved in 1, 4-dioxane (10mL) and water (2mL), sodium carbonate (359.6mg, 3.39mmol) and [1, 1-bis (diphenylphosphino) ferrocene ] dichloropalladium (99.3mg, 135.7. mu. mol) were added under nitrogen protection, and the mixture was heated to 70 ℃ for reaction for 2 hours. The reaction mixture was diluted with water (50mL) and extracted with ethyl acetate (50 mL. times.2), the organic layers were combined, the organic phase was washed with saturated brine (50mL), dried over sodium sulfate, and concentrated to give the crude product. The crude product was isolated by column on silica gel (petroleum ether: ethyl acetate (V/V) ═ 5:1-1:1, gradient elution) to give 3-chloro-6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazine (B) as a yellow solid (150mg, 34% yield).
1H NMR(400MHz,CDCl3)δ9.06(s,1H),7.55(s,1H),4.45-4.58(m,2H),4.10(s,3H),4.08(s,3H),2.24-2.29(m,1H),1.65-1.69(m,1H),1.31-1.35(m,1H),1.19-1.23(m,1H)。
LC-MS,M/Z(ESI):324.9[M+H]+。
Example 1: preparation of target Compound 1
5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (prop-1-yn-1-yl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (target compound 1)
The synthetic route for the target compound 1 is shown below:
the first step is as follows: synthesis of 4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -3- (prop-1-yn-1-yl) pyridazine (1B)
3-chloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (500mg, 1.46mmol), tributyl (prop-1-yn-1-yl) stannane (960.3mg, 2.92mmol), 1, 1-bis (diphenylphosphino) ferrocene palladium chloride (102.4mg, 0.146mmol) were dissolved in 1, 4-dioxane (10mL) under nitrogen, and then reacted at 80 ℃ for 3 hours under nitrogen. After completion of the reaction, the reaction mixture was concentrated to give a crude product. Separation and purification on silica gel column (petroleum ether: ethyl acetate (V/V) ═ 5:1-1:1, gradient elution) gave 4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -3- (prop-1-yn-1-yl) pyridazine (1B) as a yellow oil (600mg, 98% yield).
LC-MS,M/Z(ESI):347.0[M+H]+。
The second step is that: 5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (prop-1-yn-1-yl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (1)
4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -3- (prop-1-yn-1-yl) pyridazine (600mg, 1.73mmol) was dissolved in aqueous hydrochloric acid (1M, 10mL) and reacted at 70 ℃ for 10 hours. The reaction was concentrated and then separated by reverse phase high performance liquid chromatography (column: Waters Xbridge150 × 25mM × 5 μm; mobile phase: a ═ water + ammonium bicarbonate (10mM), B ═ acetonitrile; gradient: 12% -48% B, 10 min) to give 5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (prop-1-yn-1-yl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (1) (80mg, yield 14.5%) as a yellow solid.
1H NMR(400MHz,CD3OD)δ8.43(s,1H),8.01(s,1H),5.76-6.05(m,1H),2.54-2.60(m,1H),2.22(s,3H),1.86-1.88(m,1H),1.42-1.46(m,1H),1.31-1.33(m,1H).
LC-MS,M/Z(ESI):318.9[M+H]+。
Example 2: preparation of target Compound 2
5- (6- (but-1-yn-1-yl) -5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (title compound 2)
The synthetic route for the target compound 2 is shown below:
the first step is as follows: synthesis of 3- (but-1-yn-1-yl) -4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (2B)
3-chloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (200mg, 0.583mmol) was dissolved in N, N-dimethylformamide (5mL), cuprous iodide (11.1mg, 58.4. mu. mol), triethylamine (236.2mg,2.33mmol) and bis (triphenylphosphine) palladium dichloride (40.9mg, 58.4. mu. mol) were added under nitrogen, followed by butyl-1-yne (15psi) and allowed to warm to 80 ℃ for 2 hours. The reaction mixture was diluted with water (25mL) and extracted with ethyl acetate (25 mL. times.2), the organic layers were combined, the organic phase was washed with saturated brine (25mL), dried over sodium sulfate, and concentrated to give the crude product. Separation and purification on silica gel column (petroleum ether: ethyl acetate (V/V) ═ 10:1-1:1, gradient elution) gave 3- (but-1-yn-1-yl) -4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (2B) as a yellow oil (200mg, 95%).
LC-MS,M/Z(ESI):361.1[M+H]+。
The second step is that: synthesis of 5- (6- (but-1-yn-1-yl) -5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (2)
3- (cyclopropylethynyl) -4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (200mg, 0.555mmol) was dissolved in aqueous hydrochloric acid (1M, 5mL) and reacted at 50 ℃ for 0.5 hour. The reaction was concentrated and then separated by reverse phase high performance liquid chromatography (column: 3 Phenomenex Luna C1875 × 30mm × 3 μm; mobile phase: a ═ water +0.05 vol% HCl (36.5%), B ═ acetonitrile; gradient: 25% -45% B, 8 min) to give 5- (6- (but-1-yn-1-yl) -5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (2) (70.7mg, 38% yield) as a yellow solid.
1H NMR(400MHz,CD3OD)δ8.49(s,1H),8.08(s,1H),5.78-6.08(m,1H),2.59-2.65(m,3H),1.88-1.95(m,1H),1.46-1.52(m,1H),1.37-1.43(m,1H),1.32(t,3H).
LC-MS,M/Z(ESI):332.9[M+H]+。
Example 3: preparation of target Compound 3
5- (6- (cyclopropylethynyl) -5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (target compound 3)
The synthetic route for the target compound 3 is shown below:
the first step is as follows: synthesis of 3- (cyclopropylethynyl) -4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (3B)
3-chloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (200mg, 583.5. mu. mol) and cyclopropylacetylene were dissolved in N, N-dimethylformamide (5mL), cuprous iodide (11.1mg, 58.4. mu. mol), triethylamine (236.2mg,2.33mmol) and bis (triphenylphosphine) palladium dichloride (40.9mg, 58.4. mu. mol) were added under nitrogen protection, and the reaction was warmed to 80 ℃ for 2 hours. The reaction mixture was diluted with water (25mL) and extracted with ethyl acetate (25 mL. times.2), the organic layers were combined, the organic phase was washed with saturated brine (25mL), dried over sodium sulfate, and concentrated to give the crude product. Separation and purification on silica gel column (petroleum ether: ethyl acetate (V/V) ═ 10:1-1:1, gradient elution) gave 3- (cyclopropylethynyl) -4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (3B) as a yellow oil (200mg, 92% yield).
LC-MS,M/Z(ESI):373.2[M+H]+。
The second step is that: synthesis of 5- (6- (cyclopropylethynyl) -5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (3)
3- (cyclopropylethynyl) -4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (200mg, 537.1. mu. mol) was dissolved in aqueous hydrochloric acid (1M, 10mL) and reacted at 75 ℃ for 2 hours. The reaction was concentrated and then separated by reverse phase high performance liquid chromatography using (column: Phenomenex Gemini-NX C1875 × 30mM × 3 μm; mobile phase: a ═ water + ammonium bicarbonate (10mM), B ═ acetonitrile; gradient: 15% -45% B, 8 min) to give 5- (6- (cyclopropylethynyl) -5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (3) (50mg, 27% yield) as a yellow solid.
1H NMR(400MHz,CD3OD)δ8.43(s,1H),7.99(s,1H),5.78-6.07(m,1H),2.50-2.55(m,1H),1.81-1.87(m,1H),1.62-1.69(m,1H),1.41-1.46(m,1H),1.32-1.36(m,1H),1.15-1.01(m,2H),0.98-0.85(m,2H).
LC-MS,M/Z(ESI):345.2[M+H]+。
Example 4: preparation of target Compound 4
5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (3-hydroxy-3-methylbut-1-yn-1-yl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (target compound 4)
The synthetic route for the target compound 4 is shown below:
the first step is as follows: synthesis of 4- (4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazin-3-yl) -2-methyl-3-yn-2-ol (4B)
3-chloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (200.0mg, 583.6. mu. mol) and 2-methylbut-3-yn-2-ol (73.6mg, 875.3. mu. mol) were dissolved in N, N-dimethylformamide (5.00mL) under a nitrogen atmosphere, and further added with cuprous iodide (11.1mg, 58.4. mu. mol), triethylamine (236.2mg,2.33mmol) and bis (triphenylphosphine) palladium (40.9mg, 58.4. mu. mol), followed by reaction at 80 ℃ for 2 hours. After completion of the reaction, the reaction mixture was added to water (10mL), extracted with ethyl acetate (20 mL. times.2), and the organic phase was washed twice with saturated brine (50mL), after which the organic phase was dried over anhydrous sodium sulfate and concentrated to give 4- (4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazin-3-yl) -2-methyl-3-yn-2-ol (4B) as a yellow oil (140.0mg, yield 68.6%).
LC-MS,M/Z(ESI):391.2[M+H]+。
The second step is that: synthesis of 5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (3-hydroxy-3-methylbut-1-yn-1-yl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (target product 4)
4- (4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazin-3-yl) -2-methyl-3-yn-2-ol (140.0mg, 358.6. mu. mol) was dissolved in hydrochloric acid (1M,3.59mL) and reacted at 50 ℃ for 12 hours. After completion of the reaction, the reaction was directly lyophilized to give a crude product, which was isolated by reverse phase high performance liquid chromatography using (column: 3. Phenomenex Luna C1875X 30mm X3. mu.m; mobile phase: A. water +0.05 vol% HCl (36.5%), B. acetonitrile; gradient: 16% -36% B, 7 min) to give 5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (3-hydroxy-3-methylbut-1-yn-1-yl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (4) (17.5mg, yield 13.2%) as a yellow solid.
1H NMR(400MHz,CDCl3)δ8.46(s,1H),8.04(s,1H),5.82-6.11(m,1H),2.57-2.62(m,1H),1.64-1.92(m,1H),1.64(s,6H),1.47-1.51(m,1H),1.35-1.37(m,1H).
LC-MS,M/Z(ESI):363.2[M+H]+。
Example 5: preparation of target Compound 5
5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (3-methylbut-1-yn-1-yl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (target compound 5)
The synthetic route for the target compound 5 is shown below:
the first step is as follows: synthesis of 4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -3- (3-methylbut-1-yn-1-yl) pyridazine (5B)
3-chloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (253.2mg, 583.6. mu. mol) and 3-methylbut-1-yne (59.6mg, 875.3. mu. mol) were dissolved in N, N-dimethylformamide (5.00mL) under a nitrogen atmosphere, to which cuprous iodide (11.1mg, 58.4. mu. mol), triethylamine (236.2mg,2.33mmol) and bis (triphenylphosphine) palladium dichloride (40.9mg, 58.4. mu. mol) were added, followed by reaction at 80 ℃ for 2 hours. After completion of the reaction, the reaction mixture was added to water (10mL), extracted with ethyl acetate (30 mL. times.2), and the organic phase was washed twice with saturated brine (50mL), after which the organic phase was dried over anhydrous sodium sulfate and concentrated to give 4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -3- (3-methylbut-1-yn-1-yl) pyridazine (5B) as a yellow oily compound (180.0mg, 76.6% yield).
LC-MS,M/Z(ESI):375.3[M+H]+。
The second step is that: synthesis of 5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (3-methylbut-1-yn-1-yl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (target Compound 5)
4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -3- (3-methylbut-1-yn-1-yl) pyridazine (80.0mg, 213.7. mu. mol) was dissolved in hydrochloric acid (1M,2.14mL) and reacted at 40 ℃ for 12 hours. After completion of the reaction, the reaction was directly lyophilized to give 5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (3-methylbut-1-yn-1-yl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (5) (40.5mg, yield 50.4%) as a yellow solid.
1H NMR(400MHz,CDCl3)δ8.67(s,1H),8.23(s,1H),5.84-6.13(m,1H),2.99-3.03(m,1H),2.69-2.71(m,1H),2.03-2.05(m,1H),1.56-1.59(m,2H),1.35-1.37(m,6H)。
LC-MS,M/Z(ESI):347.2[M+H]+。
Example 6: preparation of target Compound 6
5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- ((1-methyl-1H-pyrazol-4-yl) ethynyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (target compound 6)
The synthetic route for the target compound 6 is shown below:
the first step is as follows: synthesis of 4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -3- ((1-methyl-1H-pyrazol-4-yl) ethynyl) pyridazine (6B)
3-chloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (200.0mg, 583.6. mu. mol) and 4-ethynyl-1-methyl-pyrazole (154.8mg,1.46mmol) were dissolved in N, N-dimethylformamide (5.00mL) under a nitrogen blanket, to which were added cuprous iodide (22.2mg, 116.7. mu. mol), triethylamine (236.2mg,2.33mmol) and bis (triphenylphosphine) palladium dichloride (81.9mg, 116.7. mu. mol), followed by reaction at 80 ℃ for 2 hours. After completion of the reaction, the reaction mixture was added to water (10mL), extracted with ethyl acetate (30mL × 2), and the organic phase was washed twice with saturated brine (50mL), after which the organic phase was dried over anhydrous sodium sulfate and concentrated to give 4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -3- ((1-methyl-1H-pyrazol-4-yl) ethynyl) pyridazine (6B) as a yellow oil (160.0mg, yield 66.5%).
LC-MS,M/Z(ESI):413.2[M+H]+。
The second step is that: synthesis of 5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- ((1-methyl-1H-pyrazol-4-yl) ethynyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (target Compound 6)
4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -3- ((1-methyl-1H-pyrazol-4-yl) ethynyl) pyridazine (160.0mg, 450.9. mu. mol) was dissolved in hydrochloric acid (1M,3.88mL) and then reacted at 50 ℃ for 12 hours. After completion of the reaction, the reaction was directly lyophilized to give a crude product, which was isolated by reverse phase high performance liquid chromatography using (column: 3. Phenomenex Luna C1875X 30mm X3 μm; mobile phase: A. RTM. +0.05 vol% HCl (36.5%), B. RTM.; acetonitrile; gradient: 18% -38% B, 7 min.) to afford 5- (5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- ((1-methyl-1H-pyrazol-4-yl) ethynyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (6) (66.8mg, 43.4% yield) as a yellow solid.
1H NMR(400MHz,DMSO-d6)δ11.65(s,1H),11.56(s,1H),8.40(d,1H),8.23(s,1H),7.96(s,1H),7.82(s,1H),5.91-6.21(m,1H),3.90(s,3H),2.50-2.56(m,1H),1.89-1.93(m,1H),1.43-1.46(m,1H),1.31-1.33(m,1H).
LC-MS,M/Z(ESI):385.2[M+H]+。
Example 7: preparation of target Compound 7
5- (6- (Cyclobutylethynyl) -5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (target compound 7)
The synthetic route for the target compound 7 is shown below:
the first step is as follows: synthesis of tributyl (cyclobutylethynyl) stannane (7A)
N-butyllithium (2.5M,7.03mL) was added dropwise to tetrahydrofuran (5mL) at-5 ℃ and the temperature was kept below 10 ℃. 6-chloro-1-hexyne (1g,8.58mmol) was added dropwise to the system at about 5 ℃ and stirred for 2 hours. Then, tri-n-butyltin chloride (3.07g,9.43mmol) was added dropwise to the system, and the reaction was carried out for 0.5 hour. The reaction was quenched with potassium fluoride solution (50mL), then extracted with ethyl acetate (50mL × 3), the organic layers were combined, dried over sodium sulfate, and concentrated to give tributyl (cyclobutylethynyl) stannane (7A) as a yellow oil (3g, 94.7% yield).
The second step is that: synthesis of 3- (cyclobutylethynyl) -4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (7B)
3-chloro-4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (200mg, 583.5. mu. mol) and tributyl (cyclobutylethynyl) stannane (7A) (323.1mg, 875.3. mu. mol) were dissolved in 1, 4-dioxane (10mL), bis (triphenylphosphine) palladium dichloride (40.9mg, 58.4. mu. mol) was added under nitrogen protection, and the temperature was raised to 80 ℃ for reaction for 3 hours. And (4) spin-drying the reaction system to obtain a crude product. Purification by silica gel column separation (petroleum ether: ethyl acetate (V/V) ═ 5:1-1:1, gradient elution) gave 3- (cyclobutylethynyl) -4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (7B) as a yellow oil (200mg, 88.7% yield).
LC-MS,M/Z(ESI):387.2[M+H]+。
The third step: synthesis of 5- (6- (cyclobutylethynyl) -5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (7)
3- (Cyclobutylethynyl) -4- ((1S,2S) -2- (difluoromethyl) cyclopropyl) -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (3) (200mg, 435.1. mu. mol) was dissolved in aqueous hydrochloric acid (1M, 4.35mL) and reacted at 50 ℃ for 12 hours. The reaction was spun dry and the crude product was separated by two reverse phase high performance liquid chromatography steps (column: 3 Phenomenex Luna C1875 x 30mm x 3 μm; mobile phase: a ═ water +0.05 vol% HCl (36.5%), B ═ acetonitrile; gradient: 29% -49% B, 7.5 min) and (column: Phenomenex Gemini-NX C1875 x 30mm x 3 μm; mobile phase: a ═ water + ammonium bicarbonate (10mmol), B ═ acetonitrile; gradient: 24% -44% B, 8 min) to give the yellow solid compound 5- (6- (cyclobutylethynyl) -5- ((1S,2S) -2- (difluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (7) (10.3mg, 6.55% yield).
1H NMR(400MHz,CD3OD)δ8.47(s,1H),8.02(s,1H),5.94(td,1H),3.39-3.48(m,1H),2.55-2.60(m,1H),2.40-2.48(m,2H),2.27-2.37(m,2H),1.99-2.12(m,2H),1.83-1.89(m,1H),1.42-1.47(m,1H),1.33-1.38(m,1H).
LC-MS,M/Z(ESI):359.1[M+H]+。
Example 8: preparation of target Compound 8
5- (6- (cyclopropylethynyl) -5- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (target compound 8)
The synthetic route for the target compound 8 is shown below:
the first step is as follows: synthesis of 3- (cyclopropylethynyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazine (8B)
3-chloro-6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazine (120.0mg, 369.5. mu. mol) and ethynylcyclopropane (24.4mg, 369.5. mu. mol) were dissolved in N, N-dimethylformamide (5.00mL) under a nitrogen atmosphere, and copper iodide (7.04mg, 36.9. mu. mol), triethylamine (149.6mg,1.48mmol) and bis (triphenylphosphine) palladium dichloride (25.9mg, 36.9. mu. mol) were added thereto, followed by reaction at 80 ℃ for 2 hours. After completion of the reaction, the reaction mixture was added to water (10mL), extracted with ethyl acetate (20mL × 2), and the organic phase was washed twice with saturated brine (50mL), after which the organic phase was dried over anhydrous sodium sulfate and concentrated to give 3- (cyclopropylethynyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazine (8B) as a yellow oil (90.0mg, 39.2% yield).
LC-MS,M/Z(ESI):355.2[M+H]+。
The second step is that: synthesis of 5- (6- (cyclopropylethynyl) -5- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (target Compound 8)
3- (cyclopropylethynyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazine (90.0mg, 253.9. mu. mol) was dissolved in hydrochloric acid (1M,2.54mL) and reacted at 50 ℃ for 12 hours. After completion of the reaction, the reaction was directly lyophilized to give a crude product, which was isolated by reverse phase high performance liquid chromatography using (column: 3. Phenomenex Luna C1875X 30mm X3 μm; mobile phase: A. RTM. water +0.05 vol% HCl (36.5%), B. RTM. acetonitrile; gradient: 21% -41% B, 7 min) to give 5- (6- (cyclopropylethynyl) -5- ((1S,2S) -2- (fluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (8) (21.4mg, 23.9% yield) as a yellow solid.
1H NMR(400MHz,CDCl3)δ8.61(s,1H),8.17(s,1H),4.32-4.86(m,2H),2.43-2.46(m,1H),1.73-1.89(m,1H),1.70-1.72(m,1H),1.09-1.12(m,2H),0.99-1.02(m,2H),0.98-0.99(m,2H).
LC-MS,M/Z(ESI):327.3[M+H]+。
Example 9: preparation of target Compound 9
5- (6- (cyclopropylethynyl) -5- ((1R,2R) -2- (difluoromethyl) cyclopropyl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (title compound 9)
The synthetic route for the target compound 9 is shown below:
the first step is as follows: synthesis of 3- (2-cyclopropylethynyl) -4- [ (1R,2R) -2- (difluoromethyl) cyclopropyl ] -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (9A)
3-chloro-4- [ (1R,2R) -2- (difluoromethyl) cyclopropyl ] -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (250mg, 729. mu. mol) and ethynylcyclopropane (120mg,1.82mmol) were dissolved in N, N-dimethylacetamide (4.00mL), and then dichlorobis (triphenylphosphine) palladium (II) (102mg, 145. mu. mol), cuprous iodide (27.7mg, 145. mu. mol) and triethylamine (295mg,2.92mmol) were added to the reaction solution and reacted at 80 ℃ for 2 hours under nitrogen atmosphere. After completion of the reaction, the reaction mixture was poured into water (5mL), extracted with ethyl acetate (20mL × 2), washed with brine (20mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated, and then separated and purified by a silica gel column (petroleum ether: ethyl acetate (V/V) ═ 10:1-1:1) to give the compound 3- (2-cyclopropylethynyl) -4- [ (1R,2R) -2- (difluoromethyl) cyclopropyl ] -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (9A) (260mg, crude product) as a yellow oily compound.
LC-MS,M/Z(ESI):373.2[M+H]+。
The second step is that: 5- [6- (2-Cyclopropylethynyl) -5- [ (1R,2R) -2- (difluoromethyl) cyclopropyl ] pyridazin-3-yl ] -1H-pyrimidine-2, 4-dione (target compound 9)
3- (2-Cyclopropylethynyl) -4- [ (1R,2R) -2- (difluoromethyl) cyclopropyl ] -6- (2, 4-dimethoxypyrimidin-5-yl) pyridazine (260mg, 451. mu. mol) was dissolved in 1M aqueous hydrochloric acid (3mL) and reacted at 50 ℃ for 12 hours. After the completion of the reaction, the reaction solution was concentrated to give a product, which was isolated by high performance liquid chromatography (column: Phenomenex luna C18150 × 40mm × 15 μm; mobile phase: a ═ water + 0.05% by volume hydrochloric acid (36.5%), B ═ acetonitrile; gradient: 25% -45%, 6.5 minutes) to give 5- [6- (2-cyclopropylethynyl) -5- [ (1R,2R) -2- (difluoromethyl) cyclopropyl ] pyridazin-3-yl ] -1H-pyrimidine-2, 4-dione (9) (41.0mg, yield 17.2%) as a yellow solid.
1H NMR(400MHz,DMSO_d6):δ11.59-11.61(m,1H),11.53(s,1H),8.33-8.35(m,1H),7.88(s,1H),5.89-6.19(m,1H),2.42-2.44(m,1H),1.81-1.85(m,1H),1.69-1.70(m,1H),1.39-1.40(m,1H),1.21-1.26(m,1H),0.99-1.01(m,2H),0.87-0.89(m,2H).
LC-MS,M/Z(ESI):345.1[M+H]+。
Example 10: preparation of target Compound 10
5- [6- (2-Cyclopropylethynyl) -5- [ (1S,2S) -2- (trifluoromethyl) cyclopropyl ] pyridazin-3-yl ] -1H-pyrimidine-2, 4-dione (target compound 10)
The synthetic route for the target compound 10 is shown below:
the first step is as follows: synthesis of (1S,2S) -2- (ethoxycarbonyl) cyclopropanecarboxylic acid (10A)
Ethyl (1S,2S) -2- (hydroxymethyl) cyclopropanecarboxylate (5.0g, 34.7mmol) was dissolved in acetonitrile (50mL), and 2,2,6, 6-tetramethylpiperidine oxide (436.3mg,2.8mmol), sodium dihydrogen phosphate (6.66g,55.5mmol), and disodium hydrogen phosphate (7.88g,55.5mmol) were added in that order at 25 ℃. Then, a sodium hypochlorite solution (0.5mL) and sodium chlorite (6.27g,69.4mmol) were dissolved in 25mL of water, and slowly added dropwise to the reaction system at 0 ℃ followed by stirring at 25 ℃ for 12 hours. The reaction system was diluted with water (100mL), followed by extraction with ethyl acetate (100 mL. times.2), and the organic layers were combined, added with saturated aqueous sodium carbonate (100mL), and stirred for 10 minutes. The organic phase was separated, the aqueous phase was adjusted to pH 2-3 with 6M hydrochloric acid solution, followed by extraction with ethyl acetate (100 mL. times.2), the organic phases were combined, the organic phase was washed with saturated brine (100mL), dried over anhydrous sodium sulfate, and concentrated to give (1S,2S) -2- (ethoxycarbonyl) cyclopropanecarboxylic acid (10A) (4.8g, 87.5% yield) as a colorless oil.
1H NMR(400MHz,CDCl3)δ10.34(br.s,1H),4.14(q,2H),2.11-2.22(m,2H),1.43-1.50(m,2H),1.25(t,3H)。
The second step is that: synthesis of ethyl (1S,2S) -2- (trifluoromethyl) cyclopropanecarboxylate (10B)
(1S,2S) -2- (ethoxycarbonyl) cyclopropanecarboxylic acid (3.0g,19.0mmol) was charged into an autoclave, sulfur tetrafluoride (9.0g,83.3mmol) was added at-78 deg.C, and then the reaction system was heated to 70 deg.C in the autoclave for 16 hours. Dichloromethane (20mL) was added to the reaction, and the organic phase was washed with saturated aqueous sodium bicarbonate (500mL), dried over anhydrous sodium sulfate, and concentrated to give ethyl (1S,2S) -2- (trifluoromethyl) cyclopropanecarboxylate (10B) as a yellow oil (1.17g, 33.9% yield).
1H NMR(400MHz,CDCl3)δ4.17-4.19(m,2H),2.10-2.20(m,1H),2.00-2.05(m,1H),1.20-1.40(m,5H).
The third step: synthesis of (1S,2S) -2- (trifluoromethyl) cyclopropanecarboxylic acid (10C)
Ethyl (1S,2S) -2- (trifluoromethyl) cyclopropanecarboxylate (1.1g,6.0mmol) was dissolved in tetrahydrofuran (10mL) and water (5mL), followed by addition of lithium hydroxide monohydrate (634mg,15.1mmol) and reaction at 80 ℃ for 6 hours. After completion of the reaction, water (20mL) was added, and extraction was performed with dichloromethane (30mL × 2), and the aqueous phase was collected, adjusted to pH 3 with 6M hydrochloric acid, and then extracted with dichloromethane (30mL × 3), and the organic phases were combined, washed with saturated brine (50mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give (1S,2S) -2- (trifluoromethyl) cyclopropanecarboxylic acid (10C) as a brown oil (500mg, 53.7% yield).
1H NMR(400MHz,CDCl3)δ9.80(br.s,1H),2.20-2.23(m,1H),2.04-2.06(m,1H),1.27-1.44(m,2H)。
The fourth step: synthesis of 3, 6-dichloro-4- ((1S,2S) -2- (trifluoromethyl) cyclopropyl) pyridazine (10D)
3, 6-dichloropyridazine (450mg,3.02mmol) and (1S,2S) -2- (trifluoromethyl) cyclopropanecarboxylic acid (465mg, 3.02mmol) were dissolved in water (15mL) and concentrated sulfuric acid (0.5mL) was added and the temperature was raised to 70 ℃ under nitrogen. Then, an aqueous solution of silver nitrate (257mg,1.51mmol,1.5mL) was added rapidly, and then an aqueous solution of ammonium persulfate (2.07g,9.06mmol,5mL) was added dropwise slowly, and the reaction was continued at 70 ℃ for 1 hour. The reaction solution was adjusted to pH 9 with aqueous ammonia, followed by extraction with ethyl acetate (40 mL. times.2), and the organic layers were combined, and the organic phase was washed with saturated brine (50mL), dried over sodium sulfate, and concentrated to give a crude product. Separation was then carried out by reverse phase high performance liquid chromatography using (column: Phenomenex luna C18150 × 40mm × 15 μm; mobile phase: a ═ water +0.1 vol% TFA, B ═ acetonitrile; gradient: 35% -65% B, 10 min) to give 3, 6-dichloro-4- ((1S,2S) -2- (trifluoromethyl) cyclopropyl) pyridazine (10D) as a yellow oil (350mg, 43.8% yield).
LC-MS,M/Z(ESI):256.9[M+H]+。
The fifth step: synthesis of 3-chloro-6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2S) -2- (trifluoromethyl) cyclopropyl) pyridazine (10E)
3, 6-dichloro-4- ((1S,2S) -2- (trifluoromethyl) cyclopropyl) pyridazine (350mg,1.32mmol) and 2, 4-dimethoxypyrimidine-5-boronic acid (343mg,1.32mmol) were dissolved in dioxane (5mL) and water (1mL), sodium carbonate (420mg, 3.96mmol) and [1, 1-bis (diphenylphosphino) ferrocene ] dichloropalladium (97mg, 132. mu. mol) were added under nitrogen, and the mixture was heated to 50 ℃ for reaction for 12 hours. The reaction mixture was diluted with water (20mL) and extracted with ethyl acetate (20 mL. times.2), the organic phases were combined, the organic phase was washed with saturated brine (50mL), dried over sodium sulfate and concentrated to give the crude product. Separation and purification on silica gel column (petroleum ether: ethyl acetate (V/V) ═ 50:1-3:1, gradient elution) gave 3-chloro-6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2S) -2- (trifluoromethyl) cyclopropyl) pyridazine (10E) as a yellow oil (300mg, 44% yield).
LC-MS,M/Z(ESI):361.0[M+H]+。
And a sixth step: synthesis of 3- (2-cyclopropylethynyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -4- [ (1S,2S) -2- (trifluoromethyl) cyclopropyl ] pyridazine (10F)
3-chloro-6- (2, 4-dimethoxypyrimidin-5-yl) -4- [ (1S,2S) -2- (trifluoromethyl) cyclopropyl ] pyridazine (500mg,1.39mmol) and ethynylcyclopropane (229mg,3.47mmol) were dissolved in N, N-dimethylacetamide (5.00mL), and then dichlorobis (triphenylphosphine) palladium (II) (194mg,277umol), cuprous iodide (52.8mg, 277. mu. mol) and triethylamine (561mg,5.54mmol) were added to the reaction solution and reacted at 80 ℃ for 2 hours under nitrogen. After completion of the reaction, the reaction mixture was poured into water (10mL), extracted with ethyl acetate (20mL × 2), washed with brine (20mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated, and then separated and purified by a silica gel column (petroleum ether: ethyl acetate (V/V) ═ 10:1-1:1) to give the compound 3- (2-cyclopropylethynyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -4- [ (1S,2S) -2- (trifluoromethyl) cyclopropyl ] pyridazine (10F) as a yellow oily compound (503mg, crude product).
LC-MS,M/Z(ESI):391.1[M+H]+。
The seventh step: 5- [6- (2-Cyclopropylethynyl) -5- [ (1S,2S) -2- (trifluoromethyl) cyclopropyl ] pyridazin-3-yl ] -1H-pyrimidine-2, 4-dione (target compound 10)
3- (2-Cyclopropylethynyl) -6- (2, 4-dimethoxypyrimidin-5-yl) -4- [ (1S,2S) -2- (trifluoromethyl) cyclopropyl ] pyridazine (503mg, 503. mu. mol) was dissolved in 1M aqueous sulfuric acid (5mL) and reacted at 50 ℃ for 12 hours. After the completion of the reaction, the reaction solution was concentrated to give a product, which was then separated by high performance liquid chromatography (column: Phenomenex luna C18150 × 40mm × 15 μm; mobile phase: a ═ water + 0.05% by volume hydrochloric acid (36.5%), B ═ acetonitrile; gradient: 30% -50%, 12 minutes) to give 5- [6- (2-cyclopropylethynyl) -5- [ (1S,2S) -2- (trifluoromethyl) cyclopropyl ] pyridazin-3-yl ] -1H-pyrimidine-2, 4-dione (10) (29.0mg, yield 15.2%) as a yellow solid.
1H NMR(400MHz,DMSO_d6):δ8.38(s,1H),7.96(s,1H),2.70-2.72(m,1H),2.32-2.34(m,1H),1.66-1.70(m,1H),1.49-1.51(m,2H),1.00-1.03(m,2H),0.82-0.84(m,2H).
LC-MS,M/Z(ESI):363.1[M+H]+。
Example 11: preparation of target Compound 11
5- (5- ((1S,2R) -2-isopropylcyclopropyl) -6- (prop-1-yn-1-yl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (target Compound 11)
The synthetic route for the target compound 11 is shown below:
the first step is as follows: synthesis of (S) -2-chloro-3-methylbutan-1-ol (11B)
(S) -2-chloro-3-methylbutyric acid (30.0g,0.22mmol) was dissolved in tetrahydrofuran (300mL), lithium aluminum hydride (9.17g,0.24mmol) was slowly added at 0-10 ℃ and after the addition was completed, the mixture was stirred at 25 ℃ for 1 hour, and then the temperature was raised to 50 ℃ for reaction for 1 hour. After completion of the reaction, the reaction mixture was cooled to 0-10 ℃ and water (9mL), a 15% aqueous solution of sodium hydroxide (9mL) and water (27mL) were added in this order. Then filtered through celite, the filter cake was washed with tetrahydrofuran (100 mL. times.3), and the filtrate was concentrated to give the crude product. Separation and purification by silica gel column (petroleum ether: ethyl acetate (V/V) ═ 5:1-2:1) gave (S) -2-chloro-3-methylbutan-1-ol (11B) as a yellow oil (8.4g, 31% yield).
1H NMR(400MHz,CDCl3)δ3.91-3.94(m,1H),3.74-3.82(m,2H),2.06-2.09(m,1H),1.99-2.05(m,1H),1.04(dd,6H).
The second step is that: synthesis of (R) -2-isopropyloxirane (11C)
Potassium hydroxide (52.1g,0.93mol) was dissolved in water (50mL), cooled to 0-5 ℃ and (S) -2-chloro-3-methylbutan-1-ol (25.0g,0.20mol) was added dropwise and reacted at 25 ℃ for 1 hour. After completion of the reaction, the reaction mixture was distilled at 25 ℃ and the fractions were collected by cooling with a dry ice ethanol bath to give (R) -2-isopropyloxirane (11C) as a yellow oil (16.0g, 91.1% yield).
1H NMR(400MHz,CDCl3)δ2.71-2.74(m,2H),2.52-2.54(m,1H),1.47-1.53(m,1H),1.04(d,3H),0.97(d,3H).
The third step: synthesis of ethyl (1S,2R) -2-isopropylcyclopropane-1-carboxylate (11D)
Triethyl phosphonoacetate (14.3g,63.8mmol) was dissolved in 1, 4-dioxane (20mL), n-butyllithium (2.5M,30.2mL) was added dropwise at 0 deg.C, and after completion of the addition, the reaction was stirred at 25 deg.C for 0.5 h, and then the reaction was transferred to a stuffer tank, followed by addition of a solution of (R) -2-isopropyloxirane (5.00g, 58.1mmol) in 1, 4-dioxane (10 mL). The closed tank is screwed down, and the temperature is raised to 145 ℃ for reaction for 12 hours. After completion of the reaction, the reaction system was cooled, followed by addition of water (100mL), extraction with methyl t-butyl ether (100 mL. times.2), drying of the organic phase over anhydrous sodium sulfate, filtration and concentration to give ethyl (1S,2R) -2-isopropylcyclopropane-1-carboxylate (11D) (7.0g, yield 80.8%) as a yellow oil.
1H NMR(400MHz,CDCl3)δ4.09-4.13(m,2H),1.36-1.39(m,1H),1.19-1.27(m,5H),1.09-1.13(m,1H),0.96-0.99(m,6H),0.69-0.75(m,1H).
The fourth step: synthesis of (1S,2R) -2-isopropylcyclopropane-1-carboxylic acid (11E)
Ethyl (1S,2R) -2-isopropylcyclopropane-1-carboxylate (7.00g,44.8mmol) was dissolved in 1, 4-dioxane (60mL) and water (60mL), followed by addition of sodium hydroxide (17.9g,448.1mmol) and reaction at 100 ℃ for 7 hours. After completion of the reaction, extraction was performed with methyl t-butyl ether (100mL × 2), the aqueous phase was collected, the pH of the aqueous phase was adjusted to 1-2 with concentrated hydrochloric acid, followed by extraction with methyl t-butyl ether (100mL × 2), the organic phases were combined, washed with saturated brine (100mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give (1S,2R) -2-isopropylcyclopropane-1-carboxylic acid (11E) (6.40g, crude product) as a yellow oil to be used in the next step as it is.
1H NMR(400MHz,CDCl3)δ1.56-1.60(m,1H),1.45-1.50(m,1H),1.37-1.40(m,1H),1.21-1.27(m,1H),1.60-1.85(m,6H),0.97-1.02(m,1H).
The fifth step: synthesis of 3, 6-dichloro-4- ((1S,2R) -2-isopropylcyclopropyl) pyridazine (11F)
3, 6-dichloropyridazine (6.27g,42.1mmol) and (1S,2S) -2- (difluoromethyl) cyclopropane-1-carboxylic acid (5.39g,42.1mmol) were dissolved in water (100mL), concentrated sulfuric acid (5.39mL) was added, and the temperature was raised to 70 ℃ under nitrogen. Then, an aqueous solution of silver nitrate (3.57g,21.0mmol,25mL) was added rapidly, and then an aqueous solution of ammonium persulfate (28.8g,126.2mmol,50mL) was added slowly dropwise, and the reaction was continued at 70 ℃ for 1 hour. After completion of the reaction, the reaction solution was adjusted to pH 9 with aqueous ammonia, followed by extraction with ethyl acetate (200 mL. times.2), and the organic layers were combined, washed with saturated brine (100mL), dried over anhydrous sodium sulfate, and concentrated to give a crude product. Separation and purification by silica gel column (petroleum ether: ethyl acetate (V/V) ═ 10:1-3:1) gave 3, 6-dichloro-4- ((1S,2R) -2-isopropylcyclopropyl) pyridazine (11F) as a yellow oil (3.20g, yield 32.9%).
LC-MS,M/Z(ESI):231.0[M+H]+。
And a sixth step: synthesis of 3-chloro-6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2R) -2-isopropylcyclopropyl) pyridazine (11G)
3, 6-dichloro-4- ((1S,2R) -2-isopropylcyclopropyl) pyridazine (2.10g,9.09mmol) and 2, 4-dimethoxypyrimidine-5-boronic acid (1.67g,9.09mmol) were dissolved in 1, 4-dioxane (10mL) and water (3mL), sodium carbonate (2.89g,27.3mmol) and [1, 1-bis (diphenylphosphino) ferrocene ] dichloropalladium (664.8mg,0.91mmol) were added under nitrogen, and the mixture was heated to 100 ℃ for reaction for 2 hours. The reaction mixture was diluted with water (100mL), followed by extraction with ethyl acetate (150 mL. times.2), the organic phases were combined, the organic phase was washed with saturated brine (100mL), dried over anhydrous sodium sulfate, and concentrated to give the crude product. Separation and purification by silica gel column (petroleum ether: ethyl acetate (V/V) ═ 10:1-2:1) gave 3-chloro-6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2R) -2-isopropylcyclopropyl) pyridazine (11G) as a yellow oil (2.00G, yield 65.7%).
LC-MS,M/Z(ESI):335.1[M+H]+。
The seventh step: synthesis of 6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2R) -2-isopropylcyclopropyl) -3- (prop-1-yn-1-yl) pyridazine (11H)
3-chloro-6- (2, 4-dimethoxypyrimidin-5-yl) -4- [ (1S,2R) -2-isopropylcyclopropyl ] pyridazine (1.10g,3.29mmol), dichlorobis (triphenylphosphine) palladium (II) (230mg, 328. mu. mol) and tributyl (prop-1-ynyl) stannane (1.30g,3.94mmol) were dissolved in N, N-dimethylformamide (10mL) and then reacted at 110 ℃ for 2 hours under nitrogen. After completion of the reaction, the reaction mixture was poured into water (20mL), followed by extraction with ethyl acetate (50mL × 2), and the organic phase was washed with brine (50mL), dried over sodium sulfate, and concentrated and purified by silica gel column separation (petroleum ether: ethyl acetate (V/V) ═ 10:1-5:1) to obtain 6- (2, 4-dimethoxypyrimidin-5-yl) -4- ((1S,2R) -2-isopropylcyclopropyl) -3- (prop-1-yn-1-yl) pyridazine (11H) as a yellow oily compound (1.00g, yield 89.1%).
LC-MS,M/Z(ESI):339.1[M+H]+。
Eighth step: synthesis of 5- (5- ((1S,2R) -2-isopropylcyclopropyl) -6- (prop-1-yn-1-yl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (11)
6- (2, 4-Dimethoxypyrimidin-5-yl) -4- ((1S,2R) -2-isopropylcyclopropyl) -3- (prop-1-yn-1-yl) pyridazine (1.00g,2.67mmol) was dissolved in hydrochloric acid (1M,5.00mL) and reacted at 50 ℃ for 12 hours. After the completion of the reaction, the reaction solution was concentrated and then separated by reverse-phase high performance liquid chromatography (column: Phenomenex luna C18150 × 40mm × 15 μm; mobile phase: a ═ water + 0.225% by volume of formic acid (99%), B ═ acetonitrile; gradient: 28% -58%, 10 minutes) to give 5- (5- ((1S,2R) -2-isopropylcyclopropyl) -6- (prop-1-yn-1-yl) pyridazin-3-yl) pyrimidine-2, 4(1H,3H) -dione (11) (295mg, yield 36.7%) as a yellow solid.
1H NMR(400MHz,CD3OD):δ8.40(s,1H),7.84(s,1H),2.22(s,3H),2.14-2.17(m,1H),1.19-1.21(m,1H),1.13-1.17(m,1H),1.09-1.11(m,1H),1.08(s,3H),1.06(s,3H),1.04-1.05(m,1H).
LC-MS,M/Z(ESI):311.1[M+H]+。
Test example 1: in vitro inhibitory activity of compound on recombinant human CD73 enzyme
The assay was performed in the presence of 25mM Tris (Biosharp; 77-86-1), 25mM MgCl2Tris-MgCl of (Nanjing chemical reagents Ltd.; 7791-18-6)2In buffer. With Tris-MgCl2buffer A3 Xstock solution of Human-CD73 (Novoprotein; C446) was prepared and added to a 96-well white plate at 20. mu.L/well to a final concentration of 0.1. mu.g/mL; with Tris-MgCl2Diluting the final concentration of the compound to be 3 multiplied mother liquor with a proper concentration gradient by buffer, adding the compound into the 96-well test white board according to 20 mu L/well, uniformly mixing, incubating at normal temperature for 30min, and setting a positive control group (without adding the compound) and a negative control group (without adding CD 73); with Tris-MgCl2buffer prepared AMP (Sigma; A1752-5G) as 3 Xmother liquor, added to the above 96-well white plate at 20. mu.L/well to a final concentration of 100. mu.M, mixed well, and incubated at 37 ℃ for 60 min; Tris-MgCl for ATP2buffer prepared ATP (Sigma; A7699-1G) as 7 Xmother liquor, added to the above 96-well white plate at a final concentration of 100. mu.M per well, mixed well, incubated for 5min, and detected with ATP-GLO kit (Promega; G7573).
The inhibition rate of the compound on Human-CD73 is calculated according to the following formula, and then the IC of the compound on the inhibition of Human-CD73 is calculated by Prism software by taking the concentration of the compound as an X axis and the inhibition rate as a Y axis50The value:
TABLE 1 test Compounds for in vitro inhibition Activity on Human-CD73 enzyme
Test compounds | IC50(nM) |
Control Compound 2 | 27.03 |
1 | 21.61 |
2 | 9.118 |
3 | 4.638 |
4 | 83.94 |
5 | 196.2 |
6 | 34.80 |
7 | 33.74 |
8 | 60.03 |
9 | 247.6 |
10 | 11.19 |
11 | 14.71 |
In vitro enzyme test results show that the compound of the invention has good inhibition effect on CD73 enzyme, and compared with a control compound, part of the compounds of the invention show more excellent inhibition effect on CD73 enzyme.
Test example 2: pharmacokinetic testing
Mouse pharmacokinetic experiments using male ICR mice, 20-25g, fasted overnight. 3 mice were taken and orally administered by gavage (10 mg/kg). Blood was collected before dosing, and at 15, 30 minutes and 1,2, 4, 8, 24 hours post-dosing; 3 mice were also administered by intravenous injection (3mg/kg), and blood was collected before administration, 15 and 30 minutes and 1,2, 4, 8 and 24 hours after administration. Blood samples, 6800g, were centrifuged at 2-8 ℃ for 6 minutes, plasma was collected and stored at-80 ℃. And (3) adding 3-5 times of acetonitrile solution containing an internal standard into the plasma at each time point, mixing, carrying out vortex mixing for 1 minute, centrifuging at 4 ℃ for 10 minutes at 13000 rpm, taking supernatant, adding 3 times of water, mixing, and taking a proper amount of mixed solution to carry out LC-MS/MS analysis. The major pharmacokinetic parameters were analyzed using the WinNonlin 7.0 software non-compartmental model.
Rat pharmacokinetic experiments were performed using male SD rats, 250-280g, fasted overnight. 3 rats were orally administered by gavage (10 mg/kg). Blood was collected before dosing, and at 15, 30 minutes and 1,2, 4, 8, 24 hours post-dosing; 3 rats were also taken and administered intravenously (3mg/kg), and blood was collected before administration, 15 and 30 minutes and 1,2, 4, 8 and 24 hours after administration. Blood samples, 6800g, were centrifuged at 2-8 ℃ for 6 minutes, plasma was collected and stored at-80 ℃. And (3) adding 3-5 times of acetonitrile solution containing an internal standard into the plasma at each time point, mixing, carrying out vortex mixing for 1 minute, centrifuging at 4 ℃ for 10 minutes at 13000 rpm, taking supernatant, adding 3 times of water, mixing, and taking a proper amount of mixed solution to carry out LC-MS/MS analysis. The major pharmacokinetic parameters were analyzed using the WinNonlin 7.0 software non-compartmental model.
TABLE 2 mouse pharmacokinetic test results
Note: -indicating not tested
The result of a mouse pharmacokinetic test shows that the compound shows excellent pharmacokinetic property, and compared with a control compound, the compound has larger exposure and good pharmacy.
TABLE 3 rat pharmacokinetic test results
Note: -indicating not tested
The result of rat pharmacokinetic experiment shows that the compound of the invention shows excellent pharmacokinetic property, and compared with a control compound, the compound of the invention has larger exposure and good drug forming property.
Claims (16)
1. A compound of formula I, tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts, or prodrugs thereof:
wherein,
m is 0,1, 2,3 or 4;
in R1Independently selected from hydrogen, halogen, hydroxy, cyano, amino, unsubstituted or substituted by RaSubstituted C1-C6Alkyl, or, unsubstituted or substituted by RaSubstituted C1-C6alkyl-O-; the quilt RaSubstituted C1-C6Alkyl, or said RaSubstituted C1-C6In alkyl-O-, said is substituted by RaThe substitution can be one or more, and R isaEach independently is the following substituent: halogen, hydroxy, cyano, amino、C1-C6Alkyl radical, C1-C6alkyl-O-, -COOH, -C (═ O) NH2(ii) a When the number of the substituents is plural, the substituents may be the same or different; when m is not 0 or 1, R1Independently are the same or different;
n is 0,1, 2 or 3;
R2selected from hydrogen, unsubstituted or substituted by RbSubstituted C1-C6Alkyl, unsubstituted or substituted by RbSubstituted C3-C6Cycloalkyl, unsubstituted or substituted by RbSubstituted 5-8 membered aryl, unsubstituted or substituted by RbSubstituted 5-8 membered heteroaryl, unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkyl, or, unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkenyl; the quilt RbSubstituted C1-C6Alkyl, said by RbSubstituted C3-C6Cycloalkyl radicals, said being RbSubstituted 5-8 membered aryl, said substituted RbSubstituted 5-8 membered heteroaryl, said substituted by RbSubstituted 4-8 membered heterocycloalkyl, or said substituted RbIn the substituted 4-8 membered heterocycloalkenyl group, the group represented by RbThe substitution can be one or more, and R isbEach independently is the following substituent: halogen, hydroxy, cyano, amino, carboxy, C3-C6Cycloalkyl radical, C1-C6Alkyl, C substituted by 1-5 identical or different halogens1-C6Alkyl, or, C1-C6alkyl-O-; when the number of the substituents is plural, the substituents may be the same or different;
said unsubstituted or substituted by RbIn the substituted 5-8 membered heteroaryl, the heteroatom is selected from one or more of N, S, O and P, and the number of the heteroatoms is 1-3; said unsubstituted or substituted by RbIn the substituted 4-8 membered heterocyclic alkyl, the heteroatom is selected from one or more of N, S, O and P, and the number of the heteroatom is 1-3; said unsubstituted or substituted by RbIn the substituted 4-8 membered heterocycloalkenyl, the heteroatoms are selected from one or more of N, S, O and P, and the number of the heteroatoms is 1-3.
2. A compound of formula I, tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts, or prodrugs thereof:
wherein,
m is 0,1, 2,3 or 4;
in R1Independently selected from hydrogen, halogen, hydroxy, cyano, amino, unsubstituted or substituted by RaSubstituted C1-C6Alkyl, or, unsubstituted or substituted by RaSubstituted C1-C6alkyl-O-; the quilt RaSubstituted C1-C6Alkyl, or said RaSubstituted C1-C6In alkyl-O-, the substituents each independently refer to one or more of the following substituents: halogen, hydroxy, cyano, amino, C1-C6Alkyl radical, C1-C6alkyl-O-, -COOH, -C (═ O) NH2(ii) a When the number of the substituents is plural, the substituents may be the same or different; when m is not 0 or 1, R1Independently are the same or different;
n is 0,1, 2 or 3;
R2selected from hydrogen, unsubstituted or substituted by RbSubstituted C1-C6Alkyl, unsubstituted or substituted by RbSubstituted C3-C6Cycloalkyl, unsubstituted or substituted by RbSubstituted 5-8 membered aryl, unsubstituted or substituted by RbSubstituted 5-8 membered heteroaryl, unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkyl, or unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkenyl; the quilt RbSubstituted C1-C6Alkyl, said by RbSubstituted C3-C6Cycloalkyl radicals, said being RbSubstitutionThe 5-to 8-membered aryl of (A), the said group consisting ofbSubstituted 5-8 membered heteroaryl, said substituted by RbSubstituted 4-8 membered heterocycloalkyl, or said substituted RbIn substituted 4-8 membered heterocycloalkenyl, the substitutions each independently refer to one or more of the following substituents: halogen, hydroxy, cyano, amino, C3-C6Cycloalkyl radical, C1-C6Alkyl, C substituted by 1-5 identical or different halogens1-C6Alkyl, or, C1-C6alkyl-O-; when the number of the substituents is plural, the substituents may be the same or different;
said unsubstituted or substituted by RbIn the substituted 5-8 membered heteroaryl, the heteroatom is selected from one or more of N, S, O and P, and the number of the heteroatoms is 1-3; said unsubstituted or substituted by RbIn the substituted 4-8 membered heterocyclic alkyl, the heteroatom is selected from one or more of N, S, O and P, and the number of the heteroatom is 1-3; said unsubstituted or substituted by RbIn the substituted 4-8 membered heterocycloalkenyl, the heteroatoms are selected from one or more of N, S, O and P, and the number of the heteroatoms is 1-3.
3. The compound of formula I, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug of claim 1 or 2, characterized in that,
when R is2Is unsubstituted or substituted by RbSubstituted C1-C6When alkyl, said C1-C6Alkyl is C1-C4Alkyl, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl;
and/or when R2Is unsubstituted or substituted by RbSubstituted C1-C6When it is alkyl, the substituent RbThe number of (2) is 1-3, preferably 1;
and/or when R2Is unsubstituted or substituted by RbSubstituted C3-C6Cycloalkyl radical, said C3-C6Cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably cyclopropyl orA cyclobutyl group;
and/or when R2Is unsubstituted or substituted by RbSubstituted 5-8 membered aryl, said 5-8 membered aryl is independently phenyl or naphthyl, preferably phenyl;
and/or when R2Is unsubstituted or substituted by RbWhen substituted 5-8 membered heteroaryl, said 5-8 membered heteroaryl is independently pyrrole, pyrazole, triazole, furan, oxazole, thiophene, thiazole, pyridine, pyrazine or pyrimidine, preferably pyrazole, furan, thiophene, pyridine;
and/or when R2Is unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkyl, said 4-8 membered heterocycloalkyl is independently azetidine, oxetane, tetrahydropyrrolyl, tetrahydrofuranyl, hexahydropyran or tetrahydro-2H-thiopyran 1, 1-dioxide, preferably azetidine or oxetane;
and/or when R2Is unsubstituted or substituted by RbWhen substituted 4-8 membered heterocycloalkenyl, said 4-8 membered heterocycloalkenyl is independently dihydropyridinyl, tetrahydropyridinyl, tetrahydropyrimidinyl, pyrrolinyl, imidazolinyl, pyrazolinyl, dihydroimidazolyl, dihydropyrazolyl, dihydrooxazolyl, dihydrooxadiazolyl, dihydrothiazolyl, dihydroisothiazolyl, dihydrothienyl, dihydropyrrolyl, 3, 4-dihydro-2H-pyranyl, dihydrofuranyl, dihydropyrazinyl, dihydropyrimidyl, or fluorodihydrofuranyl, preferably 1,2,3, 4-tetrahydropyridinyl, 1, 2-dihydropyridinyl, 1, 4-dihydropyridinyl, 1,2,3, 6-tetrahydropyridinyl, 3, 4-dihydro-2H-pyranyl, or dihydrofuranyl;
and/or, RbIs a hydroxyl group;
and/or when RbIs C1-C6When alkyl, said C1-C6Alkyl is C1-C4Alkyl, preferably methyl, ethyl, n-propyl or isopropyl;
and/or when RbWhen the halogen is F, Cl, Br, I, preferably F or Cl.
4. The compound of formula I, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug according to claim 1 or 2,
And/or when R1When halogen is used, the halogen is F, Cl, Br or I, preferably F or Cl;
and/or when R1When it is halogen, m is 0,1 or 2;
and/or when R1Is unsubstituted or substituted by RaSubstituted C1-C6Alkyl, or, unsubstituted or substituted by RaSubstituted C1-C6alkyl-O-said C1-C6Alkyl is independently C1-C4Alkyl, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl;
and/or when R1Is unsubstituted or substituted by RaSubstituted C1-C6Alkyl, or, unsubstituted or substituted by RaSubstituted C1-C6When alkyl-O-, m is 1 or 2, preferably m is 1;
and/or when R1Is as a quilt RaSubstituted C1-C6Alkyl, or, by RaSubstituted C1-C6alkyl-O-, the number of said substitutions is independently 1 to 3, preferably 2;
and/or when R1Is as a quilt RaSubstituted C1-C6Alkyl radicalOr, by RaSubstituted C1-C6When alkyl-O-, the substituents are each independently C1-C6Alkyl, or C1-C6alkyl-O-, C as described for said substitution1-C6Alkyl is independently C1-C4Alkyl, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl;
and/or when RaWhen halogen is used, the halogen is F, Cl, Br or I, preferably F or Cl.
5. The compound as shown in the formula I, the tautomer, the stereoisomer, the hydrate, the solvate, the pharmaceutically acceptable salt or the prodrug thereof according to the claim 1 or 2,
8. The compound of formula I, its tautomers, its stereoisomers, its hydrates, its solvates, its pharmaceutically acceptable salts or its prodrugs according to claim 1 or 2, characterized in that it is
Wherein,
R1independently selected from hydrogen, halogen, hydroxy, cyano, amino, unsubstituted or substituted by RaSubstituted C1-C6Alkyl, or, unsubstituted or substituted by RaSubstituted C1-C6alkyl-O-; the quilt RaSubstituted C1-C6Alkyl, or said is RaSubstituted C1-C6In alkyl-O-, the substituents each independently refer to one or more of the following substituents: halogen, hydroxy, cyano, amino, C1-C6Alkyl radical, C1-C6alkyl-O-, -COOH, -C (═ O) NH2(ii) a When the number of the substituents is plural, the substituents may be the same or different;
R2selected from hydrogen, unsubstituted or substituted by RbSubstituted C1-C6Alkyl, unsubstituted or substituted by RbSubstituted C3-C6Cycloalkyl, unsubstituted or substituted by RbSubstituted 5-8 membered aryl, unsubstituted or substituted by RbSubstituted 5-8 membered heteroaryl, unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkyl, or, unsubstituted or substituted by RbSubstituted 4-8 membered heterocycloalkenyl; the quilt RbSubstituted C1-C6Alkyl, said by RbSubstituted C3-C6Cycloalkyl radicals, said being RbSubstituted 5-8 membered aryl, said substituted RbSubstituted 5-8 membered heteroaryl, said substituted by RbSubstituted 4-8 membered heterocycloalkyl, or said substituted RbIn substituted 4-8 membered heterocycloalkenyl, the substitutions each independently refer to one or more of the following substituents: halogen, hydroxy, cyano, amino, C3-C6Cycloalkyl, C1-C6Alkyl, C substituted by 1-5 identical or different halogens1-C6Alkyl, or, C1-C6alkyl-O-; when the number of the substituents is plural, the substituents may be the same or different;
said unsubstituted or substituted by RbIn the substituted 5-8 membered heteroaryl, the heteroatom is selected from one or more of N, S, O and P, and the number of the heteroatom is 1-3(ii) a Said unsubstituted or substituted by RbIn the substituted 4-8 membered heterocyclic alkyl, the heteroatom is selected from one or more of N, S, O and P, and the number of the heteroatom is 1-3; said unsubstituted or substituted by RbIn the substituted 4-8 membered heterocycloalkenyl, the heteroatoms are selected from one or more of N, S, O and P, and the number of the heteroatoms is 1-3.
10. The compound of formula I, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof according to claim 9, wherein R is1Selected from difluoromethyl, trifluoromethyl, dichloromethyl, trichloromethyl or isopropyl;
R2selected from methyl, ethyl or cyclopropyl.
12. a pharmaceutical composition, comprising a compound of formula I, a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof according to any one of claims 1 to 11, and a pharmaceutically acceptable excipient.
13. Use of a compound according to any one of claims 1 to 11, a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, a pharmaceutical composition according to claim 12 in combination with a PD-1 antibody, a PD-L1 antibody, a CTLA-4 antibody or a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor for the manufacture of a medicament for the treatment of a CD 73-associated disease.
14. Use of a compound according to any one of claims 1-11, a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof, or a pharmaceutical composition of claim 12, for the manufacture of a medicament for the treatment of a CD 73-related disease.
15. The use according to claim 13 or 14, wherein the CD 73-related disease is cancer.
16. The use according to claim 15, wherein the cancer is bladder cancer, breast cancer, bile duct cancer, rectal cancer, colon cancer, stomach cancer, gallbladder cancer, glioblastoma, head and neck cancer, liver cancer, lung cancer, lymphoma, medulloblastoma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer or renal cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020112245927 | 2020-11-05 | ||
CN202011224592 | 2020-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114437038A true CN114437038A (en) | 2022-05-06 |
Family
ID=81362818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111305068.7A Pending CN114437038A (en) | 2020-11-05 | 2021-11-05 | Pyridazine alkyne compound and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114437038A (en) |
WO (1) | WO2022095953A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
CN114395005A (en) * | 2016-01-08 | 2022-04-26 | 艾库斯生物科学有限公司 | Modulators of extracellular 5' -nucleotidase and uses thereof |
TWI702954B (en) * | 2018-03-01 | 2020-09-01 | 美商美國禮來大藥廠 | Cd73 inhibitors |
-
2021
- 2021-11-05 CN CN202111305068.7A patent/CN114437038A/en active Pending
- 2021-11-05 WO PCT/CN2021/128905 patent/WO2022095953A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022095953A1 (en) | 2022-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111484477B (en) | Benzopyridone heterocyclic compound and application thereof | |
CN111647000B (en) | Pyrazine derivative and application thereof in inhibition of SHP2 | |
CN112105610A (en) | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | |
JP7422139B2 (en) | Tricyclic compounds that act on CRBN protein | |
CN114315839A (en) | Pyrimidinedione compounds and use thereof | |
CN114456159A (en) | Nitrogen-substituted heterocyclic thiophene compound and application thereof | |
WO2022095975A1 (en) | Cd73 inhibitor and use thereof | |
KR20210047895A (en) | KEAP1-Nrf2 protein interaction inhibitor | |
CN114456157A (en) | Nitrogen-substituted amino carbonate thiophene compound and application thereof | |
US20230142274A1 (en) | Substituted aryl compound | |
CN114456147A (en) | Oxygen substituted amino carbonate thiophene compounds | |
AU2021285467A1 (en) | N-phenylaminocarbonyl pyridino-, pyrimidino and benzo-tropanes as modulators of GPR65 | |
JP2023522725A (en) | 3-Azabicycloalkyl derivative and pharmaceutical composition containing the same | |
JP7420403B2 (en) | Compounds used as kinase inhibitors and their applications | |
WO2022037630A1 (en) | Tetracyclic derivative, method for preparing same and use thereof in medicine | |
CN114437038A (en) | Pyridazine alkyne compound and application thereof | |
CN113173924A (en) | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | |
TW202409047A (en) | Pyrido[4,3-d]pyrimidine compounds | |
WO2023143147A1 (en) | Pyridazopyridone compounds, pharmaceutical composition thereof and use thereof | |
WO2022253311A1 (en) | Hpk1 inhibitor and use thereof | |
TWI823420B (en) | Compounds useful as CDK kinase inhibitors and uses thereof | |
TWI847445B (en) | A oxazine compound, its pharmaceutical composition and application | |
CN112209933B (en) | BTK inhibitors containing 4-azacycloheptane | |
CN111718351B (en) | Oxygen-containing substituted pyrazolopyrimidine compound, pharmaceutical composition and application thereof | |
WO2023116763A1 (en) | Pyridazine compound, and pharmaceutical composition and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |